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I Abbreviations
AA ascorbic acid
Aβ amyloid-β
ABCA7 ATP-Binding Cassette, Sub-Family A, Member 7
α-CTF C-terminal fragment 
AD alzheimer’s disease
ADAM a disintegrin and metalloprotease family enzyme
AGM aorta-gonad-mesonephros
AICD APP intracellular domain 
ALP alkaline phosphatase
ANOVA analysis of variance
APH-1 anterior pharynx-defective 1 
APOE apolipoprotein E
APP amyloid precursor protein 
Arg arginine
Asp aspartic acid
avDP20 average degree of polymerization 20
BACE1 β-site APP cleaving enzyme 1
BAL1 brain-specific angiogenesis inhibitor1
BBB blood brain barrier
β-CTF C-terminal fragment
BDNF brain derived neurotrophic factor
BIN1 bridging integrator 1
BM bone marrow
BSA bovine serum albumin
C2-set constant domain
Cacl₂ calcium chloride
cAMP cyclic adenosine monophosphate
CD33 siglec-3
cDNA complementary DNA
ChAT choline acetyltransferase
CLU clusterin gene
CNS central nervous system
CpG C phosphate G
CR1 complement receptor type 1
CX3CL1 chemokine (C-X3-C motif) ligand 1
CX3CR1 CX3C chemokine receptor 1
Cy cyanine dye
DAP-12 DNAX activation protein of 12 kDa
DAPI 4´,6-diamidino-2-phenylindole
DC dendritic cells  
Abbreviation 
 
 II 
ddH₂O double-distilled water
DHE dihydroethidium
DMEM/F12 dulbecco´s modified eagle medium: nutrient mixture F-12
DMSO dimethyl sulfoxide
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EOAD early onset alzheimer’s disease
EPHA1 ephrin type-A receptor 1
F4/80 EGF-like module-containing mucin-like hormone receptor-like 1
FACS fluorescence-activated cell sorter
FAD familial alzheimer’s disease
FBS fetal bovine serum
GAD glutaraldehyde
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GDNF glial cell-line derived neurotrophic factor
GD1a disialoganglioside
GD1b disialoganglioside
GFAP glial fibrillary acidic proteins
GFP green fluorescent protein 
GM1 monosialotetrahexosylganglioside
GSK-3β glycogen synthase kinase 3 beta
GT1b trisialoganglioside
GWAS Genome-wide association studies
HCl hydrochloric acid
HEK human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hLIF human leukemia inhibiting factor
HO-1 hemeoxygenase-1 
HSC hematopoietic stem cells
Iba-I ionized calcium binding adaptor molecule I
IDE insulin degrading enzyme 
Ig immunoglobulin
IgG Immunoglobulin G
IL-34 interleukin-34
IL-1β interleukin-1β
iPS induced pluripotent stem cell
ITAM immunoreceptor tyrosine-based activation motif
ITIM immunoreceptor tyrosine-based inhibition motif
KCl potassium chloride
KDN 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid
LOAD late onset alzheimer’s disease
LPS lipopolysaccharide
LTA lipoteichoic acid  
Abbreviation 
 
 III 
Lys lysine
MDP muramyl dipeptide
MEF mouse embryonic fibroblast
MFG-E8 milk fat globule EGF factor 8 
MgCl₂ magnesium chloride
MS4A6A membrane-spanning 4-domains subfamily A member 6A
MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
NaOH sodium hydroxide
NaCl sodium chloride
NCAM neural cell adhesion molecule
Neu5Ac n-acetylneuraminic acid
Neu5Gc n-glycolylneuraminic acid
NeuN neuronal nuclei
NFT neurofibrillary tangles
nGS normal goat serum
NK natural killer
NLR nod-like receptor
NOS2 Nitric Oxide Synthase 2
OligoSia oligosialic acid
Opti-MEM eagle´ minimum essential media
P3 amyloid β- peptide 17–40/42
Pax6 paired box protein 6
PBS phosphate buffered saline
PCR polymerase chain reaction
PE R-Phycoerythrin
PFA paraformaldehyde
PICALM phosphatidylinositol binding clathrin assembly protein
PLL poly-l-lysine
PLO poly-l-ornithine
PNS peripheral nervous system
pNSC primitive neural stem cells
PolySia polysialic acid
PS phosphatidylserine
PSA-NCAM polysialylated-neural cell adhesion molecule
RAGE receptor for advanced glycation end products
ROS reactive oxygen species
RT reverse transcription
sAPPα soluble N-terminal APPα fragment
sAPPβ soluble N-terminal APP fragment
SEM standard error of mean
SHP SH2 domain-containing tyrosine phosphatase 
Sia sialic acid  
Abbreviation 
 
 IV 
Siglec sialic acid binding immunoglobulin-like lectin
SHP1 Src homology region 2 domain-containing phosphatase-1
SHP2 tyrosine-protein phosphatase non-receptor type 11
SIRPβ1 signal regulatory protein-β1
Sox1 sex determining region Y-box 1
Sox2 sex determining region Y-box 2
Src sarcoma
Syk Spleen tyrosine kinase
TGF-β transforming growth factor beta
TH tyrosine hydroxylase
TLR toll-like receptor
TNF-α tumor necrosis factor alpha
TREM2 triggering receptor expressed on myeloid cells 2
TYROBP TYRO protein tyrosine kinase binding protein
V-set variable domain
YS yolk sac
Zo1 zona occludens protein1  
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II Abstract 
Phagocytes show an over-activated complement-phagosome-NADPH oxidase (NOX) 
signaling pathway in Alzheimerʼs disease. Polysialic and oligosialic acids (polySia and 
oligoSia) are glycans composed of sialic acid monomers, which are attached to the 
outermost ends of lipids and proteins on the surface of healthy brain cells. These 
structures are recognized by sialic acid-binding immunoglobulin-like lectin (SIGLEC) 
receptors of microglia and macrophages, which contain immunoreceptor tyrosine-based 
inhibitory motifs (ITIM)-signaling and counteract the complement-phagosome-NOX 
signaling pathway.  
Here, we show that low molecular weight polysialic acid with average degree of 
polymerization 20 (polySia avDP20) binds to recombinant SIGLEC-11-Fc-fusion protein. 
In vitro, the induced pluripotent stem cell derived microglia (iPSdM) like cell line and the 
THP-1 human macrophage cell line were used as model systems of SIGLEC-11 
expressing cells. PolySia avDP20 treatment slightly reduced phagocytosis of amyloid-
β1-42 fibrils and neural debris. In addition, polySia avDP20 completely prevented 
production of reactive oxygen species (ROS) by iPSdM cells and THP-1 macrophage 
cells when stimulated with amyloid-β1-42 fibrils or neural debris. Reduction of ROS  was 
as strong as known superoxide scavenger 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox) and enzyme superoxide dismutase-1 (SOD1). By using in vitro 
neuron-iPSdM and neuron-macrophage co-culture systems, Aβ and LPS treatment 
resulted in iPSdM and macrophage neurotoxicity with loss of neurites that was 
abrogated by treatment with polySia avDP20. 
In total, data show that polySia avDP20 binds to human SIGLEC-11 and acts as an anti-
inflammatory signaling molecule on SIGLEC-11-expressing iPSdM cells and THP-1 
macrophages. 
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1 Introduction 
In this current era, the world’s elderly population is confronted with the biggest 
problematic neurodegenerative disorder, “Alzheimer’s disease (AD)”. From a neurologic 
point of view, AD is a brain disorder with three major hallmarks: formation of amyloid-β 
(Aβ) plaques, formation of neurofibrillary tangles, and activation of microglial cells; 
which all together results in loss of neuronal connections and memory impairment. 
Every factor that could have an effect on these three main hallmarks may be considered 
as a potential therapeutic agent.  
1.1 Microglia 
1.1.1 Microglia and Macrophages in CNS 
Microglial cells are the resident macrophages of the brain, which constitute about 10-
15% of the entire brain cell population. In the healthy brain, microglial cells are in 
surveillance mode and constantly explore their microenvironments. This task helps 
them recognize changes such as apoptotic material. They always interact with neurons 
to remove synaptic structure for remodelling the presynaptic components or to remove 
newborn neurons during early development [1]. In addition, microglial cells represent 
the first line of defence against invading pathogens or other types of brain tissue injury. 
To fulfill this task, they may directly remove the particles by phagocytosis or indirectly 
through inflammatory responses such as cytokine or reactive oxygen species (ROS) 
release [2].  
Other types of resident immune cells of the brain are brain macrophages such as 
perivascular macrophages, meningeal macrophages and choroid plexus macrophages, 
which can be detected with the same specific markers as microglial cells (Iba1, 
CX3CR1,F4/80); however, they have a different ontogeny [3].  
In pathological conditions or neurodegenerative diseases, in which the blood brain 
barrier (BBB) is compromised, blood monocytes and leukocytes recognize 
Introduction 
 
2 
 
chemoattractant molecules and enter to the brain to form a new population named 
exogenous macrophages [4], [5]. 
1.1.2 Origin of Microglia and Replenishment 
Del Rio-Hortega (1932) described for the first time microglia as the "third element", 
besides neurons and neuroglia (astrocytes and oligodendrocyte), in the central nervous 
system (CNS). Hortega was also the first person who postulated that microglial cells 
have a mesodermal origin [6]. Nowadays, it is believed that unlike neurons and 
macroglia (astrocytes and oligodendrocyte), which are derived from neuroectoderm, 
microglial progenitors have a mesodermal (myeloid) origin [7].  
In mice, primitive hematopoiesis occurs between E7 to E9, and leads to the appearance 
of microglial progenitors [8]. During this time, erythromyeloid progenitors appear in 
the extra-embryonic yolk sac (YS) at E7. Later on, they migrate to the brain via the 
circulatory system around E9 and populate the brain mesenchyme [9]. Definitive 
hematopoiesis occurs at E10.5, when hematopoietic stem cells (HSCs) appear in aorta-
gonad-mesonephros (AGM) region. These cells subsequently produce myeloid cells 
that are the brain macrophage and exogenous macrophage progenitors [3]. Later on, 
myeloid cells derived from HSCs populate fetal liver (E12.5) and bone marrow (after 
birth) as major hematopoietic organs [10]. 
The next debate concerned the replicative capacity of microglia and whether they are 
replicated in situ or are replenished by circulating precursor cells. Because of their 
mesodermal origin, the contribution of circulating monocytes or myeloid progenitor cells 
to the steady-state population of microglia in healthy CNS was under debate. Early 
studies, which mainly focus on transplantation of labeled bone marrow cells to irradiated 
recipients, yield to the conclusion that precursors originate from bone marrow and can 
cross BBB, where they differentiate into microglial cells [11], [12]. However, irradiation 
caused the BBB the become permeablized and, as a result, the circulating labeled bone 
marrow cells could easily enter CNS [13]. Recent findings from parabiosis experiments 
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show that under an intact BBB, recruitment of labeled bone marrow circulating cells to 
the brain of host animals is negligible [14]. Parabiosis experiments also show that under 
pathological conditions (which lead to a permeable BBB), transient recruitment of 
circulating cells to CNS occurs. However, these cells will never have a permanent 
contribution to CNS microglial pool [15]. 
In summary, microglial cells originate from primitive progenitors in the YS and migrate to 
the CNS during early embryogenesis. Their population is maintained by local precursors 
that colonize the brain before birth independent of circulating monocytes. Data from 
bone marrow transplantations have shown that during CNS inflammation or disease 
conditions there will be recruitment and differentiation of blood monocytes to microglial 
like cells [16]. 
1.2 Alzheimer’s Disease  
AD is the most common form of neurodegenerative disorder in the elderly population, 
with prevalence of around 25% in those over 90 years old [17]. AD has a well-known 
progression, which starts in brain regions responsible for learning and memory, mainly 
pyramidal cell loss in CA1 region of hippocampus [18]. The most pathologically 
accepted concept is the amyloid cascade hypothesis. According to this hypothesis, the 
pathological steps which lead to AD consist of (i) appearance of senile plaques, (ii) 
formation of neurofibrillary tangles (NFT), and (iii) microglial cell inflammatory response 
(Heppner et al. 2015). In reality, there is no border between the three steps; however, 
these steps are described separately to simplify the explanation. 
First step: The most important components of senile plaques are Aβ peptides, which 
are produced through sequential cleavage of the amyloid precursor protein (APP) (Fig 
1-1). APP cleavage can occur either in a non-amyloidogenic pathway or an 
amyloidogenic pathway. In the non-amyloidogenic (physiological) pathway, APP is first 
cleaved in the middle by an α-secretase (a disintegrin and metalloprotease family 
enzyme, ADAM), producing a soluble N-terminal APPα fragment (sAPPα) and a 
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transmembrane C-terminal fragment (α-CTF). α-CTF is then further cleaved by a γ-
secretase (multi-subunit protease complex) to generate a short peptide P3 and APP 
intracellular domain (AICD; Fig 1-1 A; [19], [20]. 
In the amyloidogenic (pathological) pathway, which leads to Aβ peptide formation, APP 
is first cleaved by a β-secretase (β-site APP cleaving enzyme 1, BACE1) at the N-
terminus of the future Aβ peptide sequence. This cleavage produces a soluble N-
terminal APPβ fragment (sAPPβ) and a transmembrane C-terminal fragment (β-CTF). 
β-CTF is further cleaved by a γ-secretase to generate Aβ and AICD (Fig 1-1 B; Moore et 
al. 2015; Zhang et al. 2011).  
 
Figure 1-1: Aβ1-42 production. In the physiological condition, APP is first cleaved by an α-
secretase and is divided into two fragments: sAPPα and α-CTF. The α-CTF piece is further 
cleaved by a γ-secretase and is cut up into the smaller peptides P3 and AICD (A). In the 
pathological condition, APP is cleaved by a β-secretase; afterwards, the β-CTF is split by a γ-
secretase to form the Aβ peptide and AICD (B).  
 
A γ-secretase is a multi-subunit protease complex, which consists of presenilin, 
nicastrin, anterior pharynx-defective 1 (APH-1) and presenilin enhancer 2 [20]. 
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Depending on the cleavage site of the γ-secretase, various lengths of Aβ (Aβ43, Aβ42, 
Aβ40, Aβ38, and Aβ37) are produced [22]. The most produced forms of Aβ are Aβ1-40 and 
Aβ1-42 peptides [23]. However, Aβ1-42 is more neurotoxic since it is hydrophobic and can 
incite fibril polymerization, leading to stable clusters. These clusters are able to produce 
even larger aggregates [24], [25].  
AD cases can mainly be divide to two groups: early onset AD (EOAD; also known 
familial AD or FAD) and late onset AD (LOAD). EOAD occurs in people between the 
ages of 30 to 60. Mutations in genes coding APP, presenilin-1 or presenilin-2 (subunits 
of γ-secretase) increase Aβ1-42 production [25] and lead to FAD. LOAD occurs usually 
above the age of 65. Recent studies showed that genetic factors have a big effect on 
LOAD progression. The most widely-known gene is APOE, which has 3 alleles. The 
APOE ε4 allele highly increases the risk of LOAD [26]. Genome-wide association 
studies (GWAS) have led to the detection of several AD risk genes (CLU, MS4A6A, 
ABCA7, EPHA1, PICALM, TREM2, BIN1, CR1, and CD33) that may increase the risk of 
AD development [27], [28]. Some of these genes, such as TREM2, CD33, and CR1, are 
expressed in microglia. This shows that the role of microglia should be considered in the 
study of LOAD.  
Second step: neurofibrillary tangles consist of clusters of microtubule-associated 
protein tau. Under physiological conditions, tau protein plays a role in stabilizing 
microtubules in a specific direction, especially in axons through mutual actions of 
kinases and phosphatases [29]. However, under pathological conditions like AD, tau 
proteins undergo modifications, predominantly hyper-phosphorylation, and lose their 
biological function. As a result, they cannot bind to microtubules and form aggregates 
inside neurons [30]. There are different points of view about the role of tau in AD. Some 
studies suggest that Aβ works upstream of tau and accelerates NFT formation [31]. On 
the other side, other studies mention that tau pathology is independent of Aβ or at least 
is needed for Aβ pathology [32].  
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Third step: In 1987, McGeer has shown that in contrast to the normal brain, where 
microglia are distributed uniformly throughout the gray and white matter, AD brains have 
microglia clustered in and around Aβ deposits [33]. 
Microglial cells show a double-edged role in AD pathogenesis. On one hand, in vitro 
studies show that microglia have a neurotoxic role. Activation of microglial cells by Aβ 
caused an increase in extracellular glutamate concentration, which contributes to 
neuronal dysfunction and death [34], [35]. In addition, Aβ can induce the production of 
pro-inflammatory cytokines (TNF-α, IL-1β) by microglial cells, which can directly impair 
neurons [36], [37]. In addition, Aβ can initiate the secretion of superoxide anions or ROS 
by a Syk kinase-dependent pathway in primary mouse microglia and THP-1 monocytes 
[38]. Aβ can also lead to peroxynitrite secretion that can induce neuronal exposure of 
the eat-me signal phosphatidylserine (PS) for microglial cells [39], [40]. Subsequently, 
microglial cells remove damaged neurons by phagocytosis. 
On the other hand, microglia can be neuroprotective via clearance of Aβ peptides and 
release of neurotrophic factors. Phagocytosis function by itself plays a pivotal role. On 
one side, phagocytosis can occur without neurotoxicity. Microglial cells, which were 
activated by Toll-like receptor-9  ligand (CpG), could increase uptake of Aβ and release 
of hemeoxygenase-1 (HO-1), an antioxidant enzyme, without producing neurotoxic 
molecules [41]. There are some molecules such as Fractalkine (CX3CL1) and 
interleukin (IL)-34, which are supposed to be secreted by neurons to modulate 
microglial function in a neuroprotective way. For example, IL-34 promotes microglial 
proliferation, clearance of soluble oligomeric Aβ via insulin degrading enzyme (IDE) (Aβ 
degrading enzyme), and induces secretion of HO-1 by microglial cells [42] (Figure1-2). 
On the other side, phagocytosis can be associated with inflammation. For example, the 
uptake of microbes leads to the production of pro-inflammatory cytokines or ROS 
release that are toxic for neurons [43].  
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Figure 1-2: Microglial cells plays a double-edged role in AD. The most evident features of 
the AD brain compared to healthy brain are the appearance of senile plaques, NFT formation, 
and activated phenotype of microglia (A). Microglial cell activation can be inflammatory and 
neurotoxic. Attachment of Aβ to its receptor on microglia can trigger release of glutamate, TNF-
α, IL-β and ROS, which are toxic to neurons (panel B right to left). On the other side, neurons 
can produce CX3CL1 and IL-34 and provoke homeostatic phagocytosis and neurotrophic 
function of microglia. This activation leads to microglial proliferation and release IDE enzyme or 
HO-1 enzyme (panel B left to right). 
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Every component, which can either reduce the inflammatory response of microglia in 
the presence of Aβ or increase Aβ uptake without inflammation could be a therapeutic 
candidate for AD. 
1.3 Polysialic Acid 
Sialic acids (Sias) are derivatives of the 9-carbone carboxylated sugar, neuraminic acid 
[44]. N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and 2-
keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid (KDN) are the metabolic precursors 
for all other Sias [45] (Fig 1-3). Sias can often form extended homopolymers of 
oligosialic acids (oligoSias) and polysialic acids (polySias) which are diverse according 
to four factors: (i) backbone components (Neu5Ac, Neu5Gc and KDN), (ii) modifications 
(acetylation, methylation, sulphation, lactylation, lactonization), (iii) position of sialic acid 
residue linkages (α 2→4, α 2→5, α 2→8 and α 2→9) and (iv) degree of polymerization 
(2-400) [46].  
 
Figure 1-3: The three main sialic acid structures derived from neuraminic acid. N-
acetylneuraminic acid (Neu5Ac), which is the most common member of Sia in human (A). N-
glycolylneuraminic acid (Neu5Gc, B) and 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid 
(KDN, C) (modified from Yamamoto 2010). 
 
Usually at the cell surface, Sias provide an acidic cap to the outermost ends of lipids 
and proteins of the glycocalyx [48]. This Sia layer causes specific biophysical properties 
such as negative charge, hydrophilicity, binding to specific factors such as complement 
factor H, and masking of cell surface receptors [45], [49]. Among the multiple functions 
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of Sias, one of the most important roles is the ligand recognition process. This 
recognition is mediated by specific receptors named SIGLEC receptors [50].  
1.3.1 Sialic Acid Binding Immunoglobulin-like Lectin Receptors 
Sialic acid binding immunoglobulin-like lectins (SIGLEC) consist of a family of cell 
surface receptors expressed on immune cells (such as macrophages, dendritic cells 
(DC), monocytes, neutrophils and microglial cells) that can recognize Sia residues and 
mediate mostly inhibitory but also activatory signaling [51]. SIGLECs are divided into 
two major subgroups: first, the evolutionary conserved subfamily which consists of 
SIGLEC-1 (sialoadhesin or CD169), SIGLEC-2 (CD22), SIGLEC-4 (myelin-associated 
glycoprotein, MAG) and SIGLEC-15, which are conserved across all mammalian 
species and share 30% sequence homology [52]. The second subgroup is the 
SIGLEC3/CD33–related subfamily, which shows 50-90% sequence similarity to CD33 in 
their extracellular part. However, they show poor species homology and different 
numbers between species because of evolutionary events [53]. For example, the 
human SIGLEC3-related group contains 11 members (SIGLEC-3, -5, -6, -7, -8, -9, -10, -
11, -12, -14, -16), and mouse contain 5 members (CD33, siglec-e, -f, -g, -h)[54]. 
All SIGLEC receptors are composed of four parts: (i) Extracellular N-terminal V-set 
immunoglobulin (Ig) domain, which is responsible for Sia recognition, (ii) variable 
number of C2-set Ig domains, (iii) one transmembrane part, and (iv) the cytoplasmic tail 
(Fig 1-4) [51], [52]. According to the transmembrane and cytoplasmic tail, SIGLECs can 
be divided into three groups: The first group of  SIGLECs, like SIGLEC-1 and -4, do not 
have any inhibitory motif in their intracellular tail. The second group (SIGLEC-2, -3, -5, -
6, -7, -8, -9, -10, -11 and -12) consist of at least one immunoreceptor tyrosine-based 
inhibition motif (ITIM) which allows them to act as inhibitory receptors (Fig. 1-4). The 
third group (SIGLEC-14, -15, -16) of SIGLECs carries a positively charged residue in 
the transmembrane region. This positive charge enables them to recruit a disulfide-
linked homodimer of DNAX-associated protein of 12 kDa (DAP-12), an adaptor protein 
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that contains an immunoreceptor tyrosine-based activatory motif (ITAM), which permits 
these SIGLECs to function as activatory receptors (Fig 1-4) [53]. 
 
Figure 1-4: Human SIGLECs. SIGLECs are type I transmembrane proteins. Each SIGLEC 
contains one N-terminal V-set Ig domain to recognize the ligand. They have variable C2-set Ig 
domains to extend from the cell surface. In the intracellular part, according to the motif they 
carry, their function can be inhibitory (contain ITIM domain) or activatory (contain positive 
residues, which enable them to recruit ITAM containing adaptor protein). Modified according to 
Pillai et al., 2012.  
 
1.3.2 ITIM / ITAM Signaling 
Upon ligand binding to SIGLECs, depending on the type of intracellular motif, de-
phosphorylation or phosphorylation processes will cause an inhibitory or activatory 
response by cells.  
There are two pairs of ITIM/ITAM-carrying receptors in SIGLEC3/CD33–related 
subfamily (SIGLEC-5 vs SIGLEC-14 and SIGLEC-11 vs SIGLEC-16). Pair receptors are 
developed to provide a balance in SIGLEC response toward ligand binding [53]. 
SIGLEC-11 and SIGLEC-16 share about 99% amino acid identity with each other in the 
extracellular domains [55]. Human brain microglia have a specific expression of 
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SIGLEC-11, which recognizes Neu5Ac α2→8 as itʼs ligand [56]. Neu5Ac α2→8  can be 
recognized by SIGLEC16 as well. 
SIGLEC-11 is neutrally charged in the transmembrane part and contains an ITIM motif in 
the intracellular part, which enables it to act as an inhibitory receptor [51]. Following 
ligand attachment to the receptor, members of the Src kinase family become activated 
and phosphorylate the ITIM motif tyrosine residues. Phosphorylated tyrosines provide 
the docking sites for SH2 domain-containing tyrosine phosphates (SHP1 and SHP2), 
which upon activation counteract functions of ITAM signaling pathways (Fig 1-5) [57]. 
 
Figure 1-5: SIGLEC-11 vs SIGLEC-16 pair. Upon ligand attachment to SIGLEC-11, the 
tyrosine within the ITIM domain will be phosphorylated by Src kinase and will provide the 
docking site for SHP-1 phosphatase. SHP-1 phosphorylation leads to the de-phosphorylation of 
downstream proteins, and downregulation of activatory signaling pathways. Alternatively, upon 
ligand binding to SIGLEC-16, it will recruit the adaptor protein TYROBP by interaction between 
positively charged lysine and negatively charged aspartic acid. TYROBP adaptor contains ITAM 
domains. ITAM domains phosphorylation will provide sites for Syk kinase and starts the 
activatory signal transduction. 
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SIGLEC-16 does not have any intracellular motif; however, it contains a positively 
charged lysine in the transmembrane part, which enables this receptor to recruit the 
ITAM-containing adaptor molecule DAP-12 (TYROBP) [51]. Upon ligand binding, the 
ITAM motif of the adaptor molecule will be phosphorylated by the Src kinase family and 
will provide the docking site for Syk kinase. This kinase will, upon phosphorylation, 
trigger several downstream signaling pathways, leading to phagocytosis or release of 
ROS (Fig 1-5) [58]. 
1.3.3 Modulation of Aβ Neurotoxicity by Sia and SIGLECs  
The human brain is a rich source of glycolipids. Gangliosides (GM1, GD1a, GD1b, 
GT1b) are members of glycolipids, which comprise ~ 0.6% of total brain lipid, and carry 
~ 75% of brain’s Sia [48]. Gangliosides, especially GM1, have been shown to be 
sufficient for Aβ binding and aggregation; they are also the main suspect in immune 
masking of Aβ plaques [59], [60]. Aβ binding to gangliosides, especially GM1, results in 
an altered secondary structure towards β-sheets folding [61]. GM1 gangliosides can 
bind to Aβ isoforms with the following affinities: Aβ1-42> Aβ40-1> Aβ1-40> Aβ1-38 [62],[64]. 
On the other hand, sialylation provide the recognition signal for microglial cells which 
carry SIGLEC-11 or SIGLEC-3 on their surface. Both of these SIGLEC receptors have 
an ITIM motif, which upon activation start immunosuppressive signals [60], [65]. The 
inhibitory signals can inhibit the function of other microglial pattern recognition 
receptors, such as TREM2 and SIRPβ1, which are amyloid plaque-associated microglial 
phagocytic receptors and signal via ITAM [66], [67]. Upon ITIM activation, phagocytosis 
is reduced, but simultaneously the Aβ induced cytokine release and ROS production are 
attenuated.  
Recent data show that SIGLEC receptors on microglia can recognize Sias on the 
neuronal glycocalyx. Siglec-e, which is a member of the mouse CD33-related SIGLEC 
family, can reduce phagocytosis and ROS release in microglial cells mediated by neural 
debris if overexpressed. In addition, in a mouse neuron-microglia co-culture system, 
siglec-e on microglial cells showed neuroprotective features by binding to Sias of intact 
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neuronal glycocalyx [68]. Moreover, activation of SIGLEC-11 in mouse microglia, which 
ectopically expresses flag-tagged human SIGLEC-11 by crosslinking with flag-specific 
antibodies, reduces gene transcription of pro-inflammatory mediators such as IL-β, 
NOS-2. In the mouse neuron-microglia co-culture system, microglial SIGLEC-11 could 
interact with Sias on the neuronal glycocalyx and reduce microglial cell neurotoxicity 
[69]. 
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1.4 Aim of the Study 
In AD, neuronal glycocalyx is changed and Aβ plaques are present. Both of these 
situations can lead to inflammatory responses of microglial cells, which are harmful for 
neurons. Previously, it has been shown that alteration in polySia of neuronal glycocalyx 
can modulate microglia functions through SIGLEC receptors present on microglial cells. 
Still, it is not clear which length of polySia as a ligand can interact with microglial 
SIGLEC-11 receptor and how this interaction can change microglial cell behavior. 
Therefore, in this study, we attempted to fulfill three different aims. 
The first aim of the thesis at hand was to investigate whether polySia could act as a 
ligand for SIGLEC-11 receptor. To fulfill this, different lengths of polySia were used and 
the response of Aβ1-42 activated microglias (iPSdM cells) toward them was studied.  
The second aim of the thesis was to explore how this specific ligand can change 
phagocytosis and superoxide production of iPSdM/macrophages toward Aβ1-42 and 
neural debris stimulation . 
The third aim of the thesis was to test whether the SIGLEC-11 ligand – polysia is 
capable of preventing the iPSdM/macrophages toxic effect mediated by Aβ1-42 or 
Lipopolysaccharide (LPS) in neuron-iPSdM or neuron-macrophage co-culture systems. 
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2 Materials and Methods 
2.1 Cells and Cultures 
2.1.1 Generation of Primitive Neural Stem Cells (pNSCs) from iPS Cells  
Human induced pluripotent stem (iPS) cells generated from MP-1 (AG Brϋstle, 
University of Bonn, Germany) were used for pluripotent neural stem cell (pNSC) 
induction by a modified protocol, which was originally described to obtain primitive 
neural precursors from human embryonic stem cells [70]. iPS cells were cultured on 
mouse embryonic fibroblast (MEF) feeder cells in iPS-knockout/serum replacement 
medium (table 2-1) to form small colonies for 2 days in an incubator with 5% CO2, 37˚C. 
Next, the medium was changed to neural stem cell medium (table 2-2) which contains 
leukaemia inhibiting factor (LIF) and three small molecules CHIR99021 (inhibitor of 
GSK-3β) and SB431542 (inhibitor of TGF-β and activin receptors), and Compound E 
(inhibitor of γ-secretase) for 10 days. The medium was changed every day. Cells were 
split by accutase and replated on Poly-L-ornithine (PLO) + Fibronectin (Fn) coated 
dishes in neural stem cell medium supplemented with LIF, CHIR99021 and SB431542 
to keep them in pluripotent state in an incubator with 5% CO2, 37˚C. 
Table 2-1 iPS knockout/serum replacement medium
Component Quantity Company
Dulbecco’s Modified Eagle Media 200 ml Gibco,
(DMEM) + factor12 (1:1) Life Technologies
 + L-glutamine + 15 mM HEPES
KnockOut serum replacement 50 ml Gibco,
Life Technologies
Non-Essential Amino Acids 2.5 ml Gibco,
Life Technologies
L-Glutamine 1.2 ml Gibco,
Life Technologies
β-mercaptoethanol 5 µl Millipore
Recombinant human FGF basic 75 µl R & D system  
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Table 2-2 neural stem cell medium
Component Quantity Company
Dulbecco’s Modified Eagle Media 250 ml Gibco,
(DMEM) + factor12 (1:1) Life Technologies
 + L-glutamine + 15 mM HEPES
Neurobasal medium 250 ml Gibco,
Life Technologies
N2 supplement 5 ml Gibco,
Life Technologies
B27 supplemet 10 ml Gibco,
Life Technologies
GlutaMAX supplement 5 ml Gibco,
Life Technologies
Human Leukemia inhibitory factor 0.5 ml Millipore
CHIR99021 0.05 ml Axon medchem
SB431542 0.05 ml Axon medchem
Compound E 0.05 ml Axon medchem  
2.1.2 Generation of Human Neurons from pNSCs 
To induce differentiation towards neurons, pNSCs were dissociated by accutase. Then, 
pNSCs were cultured on PLO + Laminin (Ln) coated 4-chamber slides in neural stem 
cell medium till cells attached and started to form small colonies in an incubator with 5% 
CO2, 37˚C. Afterwards, medium was changed to neuronal differentiation medium (table 
2-3) for 2 weeks. Medium containing the neurotrophic factors was changed every 
second day. 
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Table 2-3 neuronal differentiation medium
Component Quantity Company
Dulbecco’s Modified Eagle Media 500 ml Gibco,
(DMEM) + factor12 (1:1) Life Technologies
 + L-glutamine + 15 mM HEPES
N2 supplement 5 ml Gibco,
Life Technologies
B27 supplemet 10 ml Gibco,
Life Technologies
Cyclic adenosine monophosphate 0.15 ml Sigma-Aldrich
Ascorbic acid 0.5 ml Tocris
Glial derived neurotrophic factor 0.5 ml Prospect
Brain derived neurotrophic factor 0.5 ml Prospect  
2.1.3 iPSdM Cell Line 
Induced pluripotent stem cell-derived microglia (iPSdM) cells, a microglia-like cell line, 
were generated from human induce pluripotent stem cells. These cells show microglial 
cell surface markers such as CD11b, CD11c, CD16/32, CD36, CD40, CD45, CD49d, 
CD86, CD206 and CX3CR1. They also show functional abilities like microglial cells 
such as phagocytosis, release of ROS, release of pro-inflammatory cytokines and 
migration toward chemokines [71]. 
IPSdM cells grow in adherent culture. After thawing in pre-warmed N2 culture medium 
(table 2-4), the cell suspension was centrifuged to get rid of DMSO (1300 rpm, 3 
minutes). Then, the pellet was resuspended in N2 culture medium and kept in 10 cm2 
diameter culture dish, in an incubator with 5% CO2, 37˚C. When cultured cells reached 
90% confluency, cells were detached by trypsinization, centrifuged (1300 rpm, 3 
minutes), and resuspended in a new 10 cm2 diameter culture dish. 
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Table 2-4 N2 culture medium
Component Quantity Company
Dulbecco’s Modified Eagle Media 500 ml Gibco,
(DMEM) + factor12 (1:1) Life Technologies
 + L-glutamine + 15 mM HEPES
N2 supplement 5 ml Gibco,
Life Technologies
L-glutamine 1.2 ml Gibco,
Life Technologies
Penicillin-Streptomycin 5 ml Gibco,
Life Technologies  
2.1.4 THP1 Cell Line 
The human monocytic cell line THP-1 derived from an acute monocytic leukaemia 
patient was used to obtain macrophages. These cells were kindly provided by Prof. Veit 
Hornung (University of Bonn, Germany). After thawing in pre-warmed monocyte culture 
medium (table 2-5), the cell suspension was centrifuged to get rid of DMSO (1300 rpm, 
3 minutes). Since THP-1 monocytes are cultured in suspension, the pellet was 
resuspended in monocyte culture medium and kept in 25 cm2 flask in an incubator with 
5% CO2, 37˚C. When cultured cells reached about 1x10
6 cells/ml, the cell suspension 
was collected, centrifuged (1300 rpm, 3 minutes), and resuspended in 75 cm2 flasks. 
Table 2-5 THP-1 monocyte culture medium
Component Quantity Company
Roswell Park Memorial Institute 450 ml Gibco,
medium (RPMI) + L-glutamine Life Technologies
Fetal Calf Serum 50 ml Gibco,
Life Technologies
Penicillin-Streptomycin 5 ml Gibco,
Life Technologies
L-glutamine 5 ml Gibco,
Life Technologies
Sodium pyruvate 5 ml Gibco,
Life Technologies  
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One week after thawing, THP-1 monocytes were transfered to differentiation medium 
(table 2-6). To induce differentiation, cells were plated at appropriate density in 
differentiation medium and were incubated with 0.5 µM Phorbol-12-Myristate-13-Acetate 
(PMA) for 3 hours. Then, the attached monocytes were washed 2 times with medium 
and cultured for 48 hours more in differentiation medium. The medium was changed to 
stimulation medium (table 2-7) which contains no serum for stimulation of the cells. 
Table 2-6 THP-1 differentiation medium 
Component Quantity Company
Roswell Park Memorial Institute 450 ml Gibco,
medium (RPMI) + L-glutamine Life Technologies
Chicken serum 5 ml Gibco,
Life Technologies
N2 supplement 5 ml Gibco,
Life Technologies
Penicillin-Streptomycin 5 ml Gibco,
Life Technologies
L-glutamine 5 ml Gibco,
Life Technologies
Sodium pyruvate 5 ml Gibco,
Life Technologies  
Table 2-7 THP-1 stimulation medium 
Component Quantity Company
Roswell Park Memorial Institute 450 ml Gibco,
medium (RPMI) + L-glutamine Life Technologies
N2 supplement 5 ml Gibco,
Life Technologies
Penicillin-Streptomycin 5 ml Gibco,
Life Technologies
L-glutamine 5 ml Gibco,
Life Technologies
Sodium pyruvate 5 ml Gibco,
Life Technologies  
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2.1.5 HEK293FT Cell Line 
Human Embryonic Kidney (HEK) 293 cells are a specific cell line originally derived from 
human embryonic kidney cells from an aborted human embryo. After thawing in pre-
warmed MEF medium (table 2-8), the cell suspension were centrifuged to get rid of 
DMSO (1300 rpm, 3 minutes). Next, the pellet was resuspended in MEF medium and 
kept in 15 cm2 diameter culture dish, in an incubator with 5% CO2, 37˚C. When cultured 
cells reached 90% confluency, cells were detached by trypsinization and seeded onto 
Poly-L-lysine (PLL) coated dishes for transduction. 
Table 2-8 MEF medium
Component Quantity Company
Dulbecco’s Modified Eagle Media 450 ml Gibco,
(DMEM) + L-glutamine Life Technologies
 + 4500 mg/l D-glucose
L-glutamine 5 ml Gibco,
Life Technologies
Non-Essential Amino Acids 5 ml Gibco,
Life Technologies
Sodium pyruvate 5 ml Gibco,
Life Technologies
Fetal Calf Serum 50 ml Gibco,
Life Technologies  
2.1.6 Co-culture of Neurons with iPSdM or THP-1 Macrophages 
To prepare iPSdM/macrophages for co-culture experiments, in LPS stimulated groups, 
80% confluent dishes of either iPSdM cells or THP-1 macrophages were pre-treated for 
24 hours with 1 μg/ml LPS. Next, iPSdM/macrophages were washed once with 1x PBS, 
scraped, and counted. The appropriate number of iPSdM/macrophages were added to 
neurons with/without 1.5 µM polySia avDP20 with a 1 : 5 iPSdM/macrophages : neuron 
ratio in neuronal differentiation medium for 48 hours.  
In fibrillar Aβ1-42 stimulated groups, unbiotinylated Aβ1-42 was incubated 72 hours before 
the experiment in 37˚C to stimulate fibrillar formation. iPSdM/macrophages and 1 µM 
fibrillar Aβ1-42 were added to the neurons with/without 1.5 µM polySia avDP20 in a 1 : 5 
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iPSdM/macrophages : neuron ratio in neuronal differentiation medium for 48 hours. To 
test the antioxidant effect of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 
(Trolox), 40 µM Trolox was together with 1 µM fibrillar Aβ1-42 and iPSdM/macrophages 
to the neurons and incubated in neuronal differentiation medium for 48 hours. 
2.1.7 Debris Production 
Neural stem cells were seeded. When 90% confluency was reached, cells were 
incubated with 40 nM okadaic acid for 24 hours. Medium containing cell debris was 
collected and centrifuged (1500 rpm, 4 minutes) to aggregate the remaining cell 
membranes and washed once with 1x PBS. Then, debris was incubated with DNase to 
break down DNA and subsequently washed 2 times with 1x PBS. For phagocytosis 
experiments, debris was stained with “Dil Derivatives for Long-Term Cellular Labelling” 
Molecular Probes (1 µg/ml) according to supplier’s manual. The obtained debris was 
washed, weighed, aliquoted, and stored in -20˚C. 
 
2.2 Cellular Assays  
2.2.1 Fibrillar Aβ1-42 and Debris Phagocytosis Assays 
To get fibril forms, biotinylated Aβ1-42 diluted in PBS (1 mg/ml) was incubated for 72 
hours at 37˚C as previously described [72]. IPSdM cells were seeded at a density of 
40,000 cells per well in a chamber slide 24 hours before the experiment. THP-1 
monocytes were seeded and differentiated at a density of 100,000 cells per well in a 
chamber slide to obtain macrophages 48 hours before the experiment. 
IPSdM/macropahges were pre-incubated for 1 hour with different concentrations of 
polySia avDP20 (0.15, 0.5 and 1.5 µM), followed by 1.5 hour incubation with 2 µM 
fibrillary biotinylated Aβ1-42. Then, the cells were fixed, blocked, and incubated with 
rabbit anti-Iba1 antibody (iPSdM, table 2-17) or rat anti-CD11b antibody (macrophages, 
table 2-17) overnight at 4˚C. Afterwards, cell were washed and incubated with a 
secondary Alexa 488-conjugated antibody directed against rabbit IgG and streptavidin-
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Cy3 (iPSdM, table 2-17) or a secondary Alexa 488-conjugated antibody directed against 
rat IgG and streptavidin-Cy3 (macrophages, table 2-17) for 2 hours at room 
temperature. The staining protocol is mentioned in table 2-16 in detail. For analysis, 
images were obtained with a confocal laser scanning microscope and the fluorescent 
labeled Aβ1-42 was visualized inside the iPSdM and macrophages by 3D reconstruction. 
Percentage of the cells ingested fluorescently labeled Aβ1-42 was analyzed in 5 
randomly selected areas per condition per experiment by using ImageJ software. 
Similar to Aβ phagocytosis experiments, 40,000 iPSdM and 100,000 macrophages were 
seeded per well in a chamber slide. IPSdM and macrophages were pre-incubated for 1 
hour with different concentrations of polySia avDP20 (0.15, 0.5 and 1.5 µM), followed by 
1.5 hour incubation with 5 µg/µl stained debris. Then, the cells were fixed, blocked, and 
incubated with first and secondry antibodies as mentioned for Aβ phagocytosis. For 
analysis, images were obtained with a confocal laser scanning microscope. Percentage 
of the cells with fluorescently labeled debris was analyzed in 5 randomly selected areas 
per condition per experiment by using ImageJ software. 
2.2.2 Detection of Superoxide Production 
To measure the superoxide production by iPSdM, cells were seeded at a density of 
40,000 cells per well in 4-chamber slides. 24 hours later, cells were treated with 10 µM 
fibrillary Aβ1-42 or 5 µg/µl debris for 15 minutes with or without 1 hour polySia avDP20 
(different concentrations) pre-incubation. 
To measure the superoxide production by THP-1 macrophages, monocytes were 
seeded at a density of 100,000 cells per well in 4-chamber slides and differentiated to 
macrophages as mentioned before. 48 hours later, macrophages were treated with 10 
µM fibrillary Aβ1-42 or 5 µg/µl debris for 15 minutes with or without 1 hour polySia 
avDP20 (different concentrations) pre-incubation.  
To test the antioxidant effect of SOD1 or Trolox as positive controls, 
iPSdM/macrophages were pre-incubated for 1 hour either with 60 U/ml SOD1 or 40 µM 
Trolox, then fibrillary Aβ1-42 or debris was added to them for 15 minutes. Afterwards, 
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cells were incubated for 15 minutes with 30 µM DHE solution (diluted in Krebs-HEPES-
buffer, table 2-9) at 37˚C. Finally, cells were washed twice with Krebs-HEPES-buffer 
and fixed with 4% PFA/Glutaraldehyde (GAD) and mounted with Mowiol 4-88. Three 
pictures were taken of each condition per experiment by confocal laser scanning 
microscopy. Analyzing of the pictures has done by Image J software. 
Component concentration Company
HEPES 8.3 mM Carl Roth GmbH
NaCl 130 mM Sigma-Aldrich
KCl 5.6 mM Sigma-Aldrich
CaCl2 2 mM Sigma-Aldrich
MgCl2 0.24 mM Sigma-Aldrich
Glucose 11 mM Carl Roth GmbH
Table 2-9 Krebs-HEPES-buffer
 
2.2.3 Neurite Branch Length Analysis 
To analyze neurite branch length, co-cultures were prepared as mentioned in section 
2.1.6. After 48 hours of iPSdM:neuron co-culture incubation, cells were fixed, blocked, 
and immunostained with rabbit-anti-Iba1 and mouse-anti-β-tubulinIII antibodies (table 2-
17) overnight at 4C followed by secondary Cy3-conjugated goat antibody directed 
against rabbit IgG and Alexa488-conjugated antibody directed against mouse IgG (table 
2-17) for 2 hours at room temperature. After 48 hours of THP-1 macrophage:neuron co-
culture incubation, cells were fixed, blocked, and immunostained with monoclonal rat 
anti-CD11b and rabbit-anti-neurofilament antibodies (table 2-17) overnight at 4˚C 
followed by secondary Cy3-conjugated goat antibody directed against rat IgG and Alexa 
488-conjugated antibody directed against rabbit IgG (table 2-17) for 2 hours at room 
temperature. Five images per condition per experiment were randomly collected by 
confocal laser scanning microscopy and total lengths of neuronal branches from β-
tubulinIII or neurofilament stained neurites was determined by the NIH ImageJ/NeuronJ 
software. 
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2.3 Molecular Assays 
2.3.1 RT-PCR  
THP-1 monocytes that were kept in THP1 differentiation medium or macrophages after 
48 hours differentiation in this medium were lysed with 1 ml QIAzol. Afterwards, RNA 
was isolated using a modified phenol-chloroform based method according to table 2-10.  
Step Quantity Condition Time
Add QIAzol to cells 1 ml Room temperature 5 min
Incubation with chloroform 200 µl Room temperature 3 min
Centrifugation 13000 rpm, 4˚ C 15 min
Collect the upper colorless phase
Incubation with isopropanol (1:1) vol Room temperature 5 min
Centrifugation 13000rmp, 4˚C 20 min
Collect the sediment
Add 70% ethanol 300 µl
Centrifugation 13000rmp, 4˚C 5 min
Table 2-10 RNA isolation 
x3 
Collect the sediment, dry, and resuspend in 12µl RNase free water  
 
To obtain cDNA, the total RNA which was obtained by protocol described in table 2-10 
was used. Reverse transcription (RT) was performed by SuperScript III reverse 
transcriptase and random hexamer primers as claimed by table 2-11.  
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Prepare RT mix (I) Components Amount Company
RNA 11 µl
Hexanucleotide (mM) 1 µl Roche
dNTP 1 µl Paqlab
Start RT program Temperature Time
65˚C 5 min
4˚C 1 min
4˚C pause
Add RT mix (II) Components Amount Company
5x first-strand buffer 4 µl Invitrogen, life technologies
DTT (100mM) 2 µl Invitrogen, life technologies
Superscript® III 1 µl Invitrogen, life technologies
Continue RT program Temperature Time
25˚C 5 min
55˚C 1 h
70˚C 15 min
4˚C pause
Table 2-11 Reverse Transcription
 
 
RT-PCR reaction has been done by Taq DNA polymerase with primers mentioned in 
table 2-12. 
Gene Forward Primer (5ʻ           3ʻ) Reverse Primer (5ʻ        3ʻ)
SIGLEC11 CACTGGAAGCTGGAGCATGG ATTCATGCTGGTGACCCTGG
GAPDH CTGCACCACCAACTGCTTAG TTCAGCTCAGGGATGACCTT
Table 2-12 Primers
 
Amplification program has been done by a Biometra Thermocycler maschine as 
described in table 2-13. 
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Prepare PCR mix Components Amount Company
PCR reaction buffer 10x 5 µl Roche
dNTP 2 µl Paqlab
Forward Primer 2 µl Invitrogen
Reverse Primer 2 µl Invitrogen
Taq polymerase 0.2 µl Roche
cDNA ~ 500 ng
DEPC Treated Water up to 50 µl invitrogen
PCR program Temperature Time
94 ˚C 3 min
94 ˚C 1 min
60 ˚C 1 min
72 ˚C 1 min
72 ˚C 10 min
4 ˚C pause
Table 2-13 RT-PCR Program
x35
 
2.3.2 qRT-PCR  
To compare SIGLEC-11 transcription levels, qRT-PCR was performed with 200 ng 
cDNA, SYBR GreenEPTM qPCR SuperMix and 400 nM primers (table 2-12) in a final 
reaction volume of 25 µl. Amplification was done as mentioned in table 2-14 by a 
Mastercycler epgradient S®. Results were analyzed by the manufacturerʼs software, 
amplification specificity was checked by melting curve analysis, and relative 
quantifications were done by ∆∆Ct method. 
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Table 2-14 qRT-PCR Program
Step Temperature Time Cycle
1- Initial denaturation 95˚C 10 min
2- Amplification  Denaturation 95˚C
 Annealing 60˚C
 Elongation 72˚C
5- Inactivation 95˚C 10 min
6- Melting curve 59˚C - 95˚C 20 min
7- Final denaturation 95˚C 15 s
8- Pause 4˚C pause
x40
 
2.4 Lentivirus Generation 
For lentiviral knockdown of SIGLEC11, a 2nd generation packaging system was used. 
The lentiviral knockdown plasmid (shRNASig11: TRCN0000062842) in a human 
pLKO.1 lentiviral shRNA target gene set backbone or a pLenti 6.2/V5_DEST Gateway 
Vector without target gene were used as control vector. HEK293FT cells pre-seeded on 
PLL coated 15 cm2 dishes were transduced by SIGLEC11 knockdown plasmid or 
control plasmid mixed with packaging plasmids (psPAX2 and pMD2.G) as described in 
table 2-15.  
Step Components Amount Time Company
1- Plasmid mix H₂O 1300 µl
for 20 ml Advanced DMEM medium Plasmid 40 µg Open Biosystem
plus 25µM chloroquine Packging plasmid 20 µg Addgene
(psPAX2)
Envelop plasmid 20 µg Addgene
(pMD2.G) 
CaCl₂ (2.5 M) 133 µl
Complex formation 2xHBS 1300 µl 15 min
2- Add the whole plasmid mix 5 h
to the dish
3- Change the medium to 20 ml 48 h
normal MEF 
4- harvest the virus
Table 2-15 Lentivirus generation
5 min
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For precipitation of viral particles, the virus-containing medium was collected and filtered 
(0.4 mm filter). Afterwards, the medium was mixed and incubated for 1.5 hour on ice 
with 8.5% polyethylenglycol, 0.3 M NaCl and PBS. Next, the solution was centrifuged at 
4500 rpm for 30 minutes. At the end, the viral particle-containing pellet was 
resuspended in 1x PBS and added to THP-1 monocytes. After 48 hours, the transduced 
cells were selected by 1 µg/ml puromycin. The efficiency of knockdown was checked by 
FACS analysis. THP-1 cells transduced by either SIGLEC11 plasmid or control plasmid 
after differentiation to macrophages were used for further analysis. 
 
2.5 Immunological Techniques 
2.5.1 Immunocytochemistry (ICC) 
For cell culture immunostaining, cells were washed once with 1x PBS. Afterwards, all 
the stainings were done according to the protocol as mention in table 2-16. Antibodies 
used in satinings are mentioned in table 2-17. Images were taken by confocal laser 
scanning microscopy or Fluorescence microscopy. 
Step Components Time Temperature
Fixation 4% PFA 15 min Room temperature
Washing (3times) 1x PBS
Blocking 10% BSA 1 h Room temperature
5% nGS 
0.1% Triton 100x
Primary antibody in PBS overnight 4˚C
Washing (3times) 1x PBS
Secondary antibody in PBS 2 h Room temperature
Washing (3times) 1x PBS
Mounting Mowiol
Table 2-16 ICC Protocol
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Antibody Type Host Specificity Working Company
conc.
Anti-NeuN 1 st mouse mouse/human 10 µg/ml Millipore
monoclonal
β-tubulin III 1 st mouse rat/human 1 µg/ml Sigma-Aldrich
monoclonal
β-tubulin III 1 st chicken mouse/human 1 µg/ml Millipore
polyclonal
CD11b (Integrin alpha-M) 1 st rat mouse/human 1 µg/ml BD Biosciences
monoclonal
ChAT 1 st goat mouse/human 2 µg/ml Millipore
polyclonal
GABA 1 st rabbit rat/human 1 µg/ml Sigma-Aldrich
polyclonal
GFAP 1 st rabbit cow/human 1 µg/ml Dako
polyclonal
Iba-1 1 st rabbit mouse/human 1 µg/ml Wako
polyclonal
Ki67 1 st mouse human 10 µg/ml Dako
monoclonal
MAP2 1 st rabbit mouse/human 1 µg/ml Millipore
polyclonal
Nestin 1 st mouse human 10 µg/ml R&D system
monoclonal
Neurofilament 200 1 st rabbit mouse/human 1 µg/ml Sigma-Aldrich
polyclonal
Olig2 1 st rabbit mouse/human 1 µg/ml Millipore
polyclonal
Pax 6 1 st rabbit mouse/human 10 µg/ml Covance
polyclonal
Siglec-11 1 st mouse human 2 µg/ml Abmart
monoclonal
Sox1 1 st rabbit mouse/human 10 µg/ml Millipore
polyclonal
Sox2 1 st mouse mouse/human 10 µg/ml R&D system
monoclonal
Tyrosine Hydroxylase 1 st rabbit mouse/human 1 µg/ml Sigma-Aldrich
monoclonal
Zo1 1 st rabbit mouse/human 2 µg/ml Invitrogen
polyclonal
Table 2-17 Antibodies
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Alexa 488-conjugated 2 nd chicken 2 µg/ml life technologies
Alexa 488-conjugated 2 nd goat 2 µg/ml Invitrogen
Alexa 488-conjugated 2 nd rabbit 2 µg/ml Invitrogen
Alexa 488-conjugated 2 nd rat 2 µg/ml Invitrogen
Cy3-conjugated 2 nd mouse 2 µg/ml Dianova
Cy3-conjugated 2 nd rabbit 2 µg/ml Dianova
Cy3-conjugated 2 nd rat 2 µg/ml Dianova
PE-conjugated 2 nd mouse 2 µg/ml Jackson Immuno 
Research  
2.5.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
For ELISA, biotinylated polySia avDP20 had to be produced (table 2-18). PolySia 
avDP20 was coupled with a biotin molecule at the N-terminus of the polySia avDP20 
chain. Biotinylated-dextran with same molecular weight was used as a control. 
Step Components Time Comments Company
Oxidation Sodium Periodate (NaIO4) 30 min in dark at 4˚C Sigma-Aldrich
0.02 M
diluted in oxidation buffer
Washing HiTrap Desalting, 5 x 5 ml 5 times (25ml GE Healthcare
1x PBS) Life Sciences
Hydrazination EZ-Link™ Hydrazide-Biotin 2 h at Room teperature Thermo Scientific
12.9 mg/ml
dilute in DMSO
Washing wash the column 5 times (25ml 
1x PBS)
Purification biotinylated polySia avDP20 load to the column
wash through with
5ml 1xPBS
Oxidation buffer: 0.1 M Natrium acetate (C2H3NaO2)
Table2-18 Biotinylation Protocol
 
Different concentrations of biotinylated-polySia avDP20  (0.01, 0.05, 0.25, 1.25, 6.25 
µg/ml) or biotinylated-dextran (0.01, 0.05, 0.25, 1.25, 6.25 µg/ml) were used to test the 
binding affinity to the recombinant human SIGLEC-11 Fc-fusion (rhSIGLEC-11/Fc) 
protein coated plate according to table 2-19.  
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Step Components Concentration Time Temperature Company
Coat plate Protein A 10 µg/ml overnight 4˚C Thermo Scientific
Washing 1x PBS +
 0.05 % tween20
Blocking 3% BSA 1 h Room teperature
Coat receptor SIGLEC11-Fc 5 µg 2 h Room teperature R&D system
Washing 1x PBS +
 0.05 % tween20
Blocking 3% BSA 1 h Room teperature
Add ligand biotinylated - polySia different conc. 2 h Room teperature
avDP20 or
biotinylated - dextran
Washing 1x PBS +
 0.05 % tween20
First reaction HRP 1:5000 1 h Room teperature Pharmingen
Washing 1x PBS +
 0.05 % tween20
Second reaction TMB 100 µl 15 min Room teperature Sigma-Aldrich
Stop reaction HCL 1N
x 3
x 3
x 3
x 3
Read the plate with ELISA plate reader (PerkinElmer) at 450 nm 
Table 2-19 ELISA Protocol
 
2.5.3 Fluorescence-Activated Cell Sorting (FACS) 
The same number of iPSdM and THP-1 macrophages were collected to study surface 
expression of SIGLEC-11. Afterwards, samples were prepared as stated in table 2-20. 
SIGLEC-11 expression was measured by a BD FACSCalibur and data was analyzed by 
the FlowJo 8.7 Software. 
Step Components Time Temperature
Washing 1x PBS
First antibody in PBS 1 h 4˚C
isotype control
PBS control
Washing 1x PBS x2
Secendary antibody PE-conjugated Ab 30 min 4˚C
Washing 1x PBS x2
Table 2-20 FACS Protocol
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2.5.4 MTT Assay 
Cell viability was determined by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. IPSdM cells were treated for 20 hours with different 
concentrations of distinct sialic acid chain lengths. Afterwards, yellow MTT was added 
to the cells and incubated for more 4 hours. At the end of this time, the purple MTT 
formazan was produced by living cells. The reaction was stopped by addition of 
isopropanol with HCl (0.04 N). Isopropanol dissolves formazan to give a homogeneous 
blue solution suitable for absorbance measurement, which was determined by a 
spectrophotometer at a wavelength of 570 nm.  
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2.6 Other Materials 
2.6.1 Technical Equipment 
Equipment Article Company
Autoclave Systec D150 Systec GmbH
Automatic Pipettes 1, 10, 100, 1000 μl Thermo Scientific
Centrifuge Megafuge 1.0R Heraeus Holding GmbH
Centrifuge MCF 2360 LMS
Electrophoresis Power Supply EPS 301 Amersham Bioscience
Electrophoresis 40-0911 Paqlab Biotechnologies
Flow Cytometer BD FACSCaliber BD Bioscience
Freezer (-20˚C) Premium Liebherr
Freezer (-20˚C) Profiline GG5260 Liebherr
Freezer (-80˚C) Herafreeze Heraeus Holding GmbH
Fridge (4˚C) Medline LKUv 1612 Liebherr
Gel Imaging System ChemiDoc Bio-Rad
Incubator Hera Cell 150 Heraeus Holding GmbH
Laminar flow hood Hera Safe Kendo Laboratory producs GmbH
Microscope Confocal Olympus IX81 Olympus
Microscope Axioskop HBO 50 Carl Zeiss AG
Microscope Apotom Carl Zeiss AG
Microwave Oven Severin 800 SEVERIN Elektrogeräte
N2 Tank MVE 611 German-cryo
Peristaltic Pump Pump drive PD 5001 Heidolph
PH-meter CG840 Schott
Pipetteboy Cell Mate II Thermo Fische Scientific Inc.
Scale Acculab Sartorius
Shaker KS-15 control Edmund Buhler GmbH
Spectrophotometer Envision Multiplate Reader Perkin Elmer
Spectrophotometer NanoDrop 1000 Thermo Scientific
Thermocycler T3 Biometra
Thermoshaker Thermomixer compact Eppendorf AG
Ultracentrifuge Sorvall Discovery 90 SE HITACHI
Ultracentrifuge Sorvall RC 6+ Thermo Scientific
Ultracentrifuge Sorvall 5B Plus Thermo Scientific
Vaccum controller VaccuHandControl Vaccumbrand
Vaccum pump Vaccu-lan network for lab Vaccumbrand
Vortex 2X² Velp Scientifica
Waterbath WB/OB7-45 Memmert GmbH & CoKG  
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2.6.2 Consumables 
Product Specification Company
Cell Culture Pipette 5, 10, 25 ml Sarstedt
Cell Scraper 17 mm Sarstedt
Chamber Slides Lab-Tek 4-chambers Nalge Nunc
Culture dish 35, 100, 150 mm Sarstedt
Culture dish 6-well plate Greiner Bio One
Culture flasks 25, 75 cm² Sarstedt
Erlenmeyer flask 250 ml Schott-Duran
Filter 0.22 μm Sarstedt
Filter 0.45 μm Corning Inc.
Glass bottle 100, 500, 1000 ml Schott-Duran
Gloves Micro-touch Ansell
IHC Glass cover slips 24 x 60 mm Engelbrecht
Lables Tough-Spots 3/8ˮ DiversifiedBiotech
Neubauer counting-chamber 0.100 mm Paul Marienfeld GmbH
Parafilm M Sigma-Aldrich
Pasteur pipettes glass Brand
Pasteur pipettes plastic Ratiolab
Pipette tips 10, 100, 1000 μl Starlab GmbH
QPCR Optical Adhesive Film QPCR seal Paqlab Biotechnologies
QPCR plates Semi-Skirted 96 wells Paqlab Biotechnologies
Scalpel Feather disposable scalpel Thermo Fisher Scientific 
Syringe 1, 50 ml BD Bioscience
Tubes 0.2 ml; 8-strip Biozym Scientific GmbH
Tubes 0.5, 1.5, 2 ml Biozym Scientific GmbH
Tubes 1.8 ml cryotubes Nalge Nunc
Tubes 5ml (flow cytometry) Sarstedt
Tubes 15, 50 ml Sarstedt  
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2.6.3 Chemicals and Reagents 
Product Company
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich
Accutase PAA
Agarose Biozym Scientific GmbH
biotinylated Amyloid-β 1-42 Bachem
Amyloid-β 1-42 Bruker
Bovine Serum Albumin (BSA) Sigma-Aldrich
Deoxynucleotide triphosphates (dNTP) 10 mM Paqlab Biotechnologies
Dihydroethidium (DHE) Thermo Fisher Scientific
Dil Derivatives for Long-Term Cellular Labelling (Dil) Thermo Fisher Scientific
Dimethyl sulfoxide (DMSO) Roche
Ditiothreiton DTT 10 mM Invitrogen
DNA ladder 100 bp Roche
Ethanol 99% Carl Roth GmbH
Ethidium bromide Carl Roth GmbH
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH
Glycerol 99% Sigma-Aldrich
Hexanucleotide mix 10x Roche
Iso-propanol 99% Sigma-Aldrich
Lipopolysaccharide (LPS) InvivoGen
Media Advanced DMEM Gibco
Media DMEM/F-12, HEPES Gibco
Media DMEM high glucose Gibco
Media Opti-MEM Gibco
Media Neurobasal® Gibco
Media RPMI Gibco
Mounting reagent Mowiol 4-88 Sigma-Aldrich
Normal goat serum Sigma-Aldrich
Paraformaldehyde (PFA) Merk & Co., Inc.
Phosphate Buffer Saline (PBS) Gibco
Phorbol-12-Myristate-13-Acetate (PMA) Sigma-Aldrich
Poly-L-lysine (PLL) Sigma-Aldrich
Poly-L-ornithine (PLO) Sigma-Aldrich
QIAzol® Qiagen
Superoxide dismutase from bovine erythrocytes (SOD1) Serva
Tris Carl Roth GmbH
Triton X-100 Sigma-Aldrich
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) Cayman
Trypan blue 0.4% Gibco
Trypsin 0.25% Gibco
Tween Sigma-Aldrich
β-mercaptoethanol 99% Carl Roth GmbH  
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2.6.4 Kits 
Product Company
Colorimetric (MTT) kit for cell survival an proliferation Millipore
KAPA™ Mouse Genotyping Hot Start Kit Peqlab 
REDExtract-N-Amp™ Tissue PCR Kit Sigma-Aldrich
RNeasy Mini Kit Qiagen  
 
2.7 Statistical Analysis  
Data are presented as mean +/- SEM (standard error of mean) of at least three 
independent experiments. Data were analyzed by SPSS 20 software followed by either 
t-test for two samples or One-Way ANOVA followed by Bonferroni post hoc tests. 
Results are considerd significant if *,P<0.05; **,P<0.01; ***,P<0.001. 
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3 Results  
3.1 SIGLEC-11 Receptor and PolySia avDP20 as Itʼs Ligand 
3.1.1 SIGLEC-11 Expression on iPSdM Cells and THP1 Macrophages 
SIGLEC-11 is expressed on human brain microglial cells [56]. Accordingly, to test the 
suitability of cell-lines, SIGLEC-11 gene expression was analyzed in iPSdM cells and 
THP-1 monocytes/macrophages via RT-PCR as mentioned in section 2.3.1. The human 
monocytic cell line THP-1, derived from an acute monocytic leukaemia patient, was 
differentiated by PMA to macrophages as a model system for human tissue 
macrophages (more details in section 2.1.4). IPSdM cell line is an induced pluripotent 
stem cell derived microglial like cells, which used as a model system for human 
microglial cells (more details in section 2.1.3). The RT-PCR outcome showed clear 
expression of SIGLEC-11 in all cells lines (Fig 3-1 A). Further comparison of mRNA 
levels between THP-1 monocytes and macrophages was performed by qRT-PCR as 
stated in section 2.3.2. Data showed that SIGLEC-11 mRNA expression increased from 
1 +/- 0.36 fold change in monocytes to 4.8 +/- 0.99 fold change in macrophages 
(p=0.026; Fig 3-1 B). 
 
Figure 3-1: SIGLEC-11 gene expression. SIGLEC-11 gene expression in iPSdM cells, THP1 
monocytes and macrophages. Representative images out of at least three independent 
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experiments; GAPDH is the internal control and mouse embryonic stem cell derived microglial 
cells (ESdM) cDNA is the negative control (A). SIGLEC-11 gene expression comparison in 
THP-1 monocytes and THP-1 macrophages (B). Data are presented as mean +/- SEM of at 
least three independent experiments and were analyzed using t-test for independent samples. *, 
p<0.05. 
 
Afterward, SIGLEC-11 protein expression in iPSdM cells and THP-1 macrophages was 
evaluated as mentioned in section 2.5.3. Results showed that in a normal culture 
situation, around 30% of iPSdM cells and 35% of THP-1 macrophages express 
SIGLEC-11 (Fig 3-2).  
 
Figure 3-2: SIGLEC-11 protein expression. Expression of SIGLEC-11 protein on the cell 
surface of iPSdM cells with isotype control (A) and a SIGLEC-11 specific monoclonal antibody 
(B). Expression of SIGLEC-11 protein on the cell surface of THP-1 macrophages with isotype 
control (C) and a SIGLEC-11 specific monoclonal antibody (D). Representative images out of at 
least three independent experiments. 
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3.1.2 OligoSias Do Not Prevent Superoxide Production 
One feature of microglial cells is their ability to produce ROS upon Aβ stimulation, which 
is directly toxic for neurons [73][74]. To investigate ROS production upon fibrillar Aβ1-42 
stimulation, iPSdMs were pre-incubated for 1 hour with monoSia and oligoSias (triSia 
and hexaSia) and were then stimulated for 15 minutes with fibrillar Aβ1-42. The ROS 
production was measured by DHE staining (described in section 2.2.2). Aβ1-42 
stimulation significantly increased ROS production (1.4 +/- 0.1 fold) compared to the 
control group (1 +/- 0.06; p=0.004; Fig 3-3). Pre-incubation with monoSia and oligoSias 
(triSia and hexaSia) could not prevent the Aβ1-42 effect (mono: 1.10 +/- 0.06 fold, tri: 
1.22 +/- 0.1 fold, hexa: 1.25 +/- 0.07 fold; Fig 3-3). 
 
Figure 3-3: OligoSias cannot prevent superoxide production. Aβ1-42 treatment leads to 
significant superoxide production while monoSia, triSia, and hexaSia pre-incubation did not 
prevent this effect. Data are presented as mean +/- SEM of at least three independent 
experiments and were analyzed using one-way ANOVA (Bonferroni). **, p<0.01. 
 
3.1.3 PolySia avDP20 and PolySia avDP 60 Prevent Superoxide Production 
To examine if longer sizes of polySias were able to hamper the fibrillar Aβ1-42 effect or 
not, the synthesized polySias that had been produced in our laboratory, by Dr. Jens 
Kopats, were used. These polySias were homopolymers of α 2→8 linked Sias with 
average degree of polymerizations of 20, 60, and 180 (polySia avDP20, avDP60, and 
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avDP180). Pre-incubation with both polySia avDP20 and polySia avDP60 were able to 
reduce the superoxide production (Fig 3-4). To determine the optimal concentrations, 
different concentrations of polySia avDP20, avDP60, and avDP180 (0.15 µM, 0.5 µM, 
1.5 μM) were used. As demonstrated in Fig 3-4, polySia avDP20 incubation prevented 
fibrillar Aβ1-42 induced superoxide production at the concentrations of 0.5 μM and 1.5 
μM (1.08 +/- 0.07 fold; p=0.038 and 0.98 +/- 0.04 fold; p<0.001, respectively) and 
polySia avDP60 at the concentration of 0.5 μM (0.96 +/- 0.05 fold; p<0.001) in 
comparison to fibrillar Aβ1-42 (1.4 +/- 0.1; Fig 3-4). Despite the strong effects of polySia 
avDP20 and avDP60, different concentrations of high molecular weight polySia (polySia 
avDP180) pre-incubation did not reduce the superoxide production (Fig 3-4). 
 
Figure 3-4: PolySias avDP20 and avDP60 are able to significantly reduce superoxide 
production. DHE intensity measurements showed that 0.5 µM and 1.5 μM of polySia avDP20 
and 0.5 μM of polySia avDP60 pre-incubation significantly prevented fibrillar Aβ1-42 induced 
superoxide production. PolySia avDP180 pre-incubation did not reduce the superoxide 
production induced by fibrillar Aβ1-42. Data are presented as mean +/- SEM of at least three 
independent experiments and were analyzed using one-way ANOVA (Bonferroni). *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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DHE results showed that both polySia avDP20 and avDP60 prevent superoxide 
production upon fibrillar Aβ1-42 stimulation. To receive information about changes in 
metabolic activity of the cells, iPSdM were incubated with different concentrations of 
polySia avDP20, avDP60, and avDP180 (0.15 µM, 0.5 µM, 1.5 μM) for 24 hours and an 
MTT assay was performed as mentioned in section 2.5.4. PolySia avDP60 and 
avDP180 at 1.5 µM reduced the metabolic activity of iPSdM cells from 1 +/- 0.04 to 0.66 
+/- 0.04 fold (p=0.037), and 0.71 +/- 0.02 fold (p=0.008), respectively (Fig 3-5). The 
concentration of 1.5 µM polySia avDP20 was chosen for further experiments. Modified 
from [75]. 
 
Figure 3-5: PolySias avDP60 and avDP180 are able to significantly reduce iPSdM cells 
metabolic activity. Metabolic activity measurements of iPSdM cells showed that 1.5 µM of 
polySia avDP60 and avDP180 reduced the metabolic activity of iPSdM cells. Data are 
presented as mean +/- SEM of at least three independent experiments and were analyzed using 
one-way ANOVA (Bonferroni). *, p<0.05; **, p<0.01. 
 
3.1.4 PolySia avDP20 Directly Binds to SIGLEC-11 Receptor 
To investigate direct binding of the SIGLEC-11 receptor to polySia avDP20, a 
rhSIGLEC-11/Fc plate was used. Different concentrations of biotinylated polySia 
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avDP20 (molecular weight between 4 and 8 kDa), which was produced according to the 
table 2-18, were added to the plate. Biotinylated dextran as a linear polysaccharide with 
a similar molecular weight (~ 5 kDa) was used as the control. ELISA was done as 
mentioned in table 2-19. Results showed that polySia avDP20 bound to the rhSIGLEC-
11/Fc fusion protein in a concentration dependent manner, while no binding of dextran 
was observed. The relative binging to SIGLEC-11 shows the measured values of the 
OD450 from the ELISA. In detail, 0.01 µg/ml, 0.05 µg/ml, 0.25 µg/ml, 1.25 µg/ml, and 
6.25 µg/ml polySia avDP20 displayed binding to rhSIGLEC-11/Fc as 0.31 +/- 0.01 fold, 
1.03 +/- 0.01 fold, 3.14 +/- 0.04 fold, and over saturated respectively. In comparison, 
0.01 µg/ml, 0.05 µg/ml, 0.25 µg/ml, 1.25 µg/ml, and 6.25 µg/ml biotinylated dextran 
showed binding to rhSIGLEC-11/Fc as 0.12 +/- 0.01 fold, 0.11 +/- 0.006 fold, 0.11 +/- 
0.005 fold, and 0.10 +/- 0.005 fold respectively (Fig 3-6).  
 
Figure 3-6: Direct binding of biotinylated polySia avDP20 to SIGLEC-11. ELISA 
measurements show the direct interaction between polySia avDP20 and SIGLEC-11/Fc fusion 
protein, while the binding of biotinylated dextran was negligible. Data are presented as mean +/- 
SEM of at least three independent experiments and were analyzed using one-way ANOVA 
(Bonferroni). ***, p<0.001. 
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3.2 PolySia avDP20 Modulates Macrophage Function via SIGLEC-11 Receptor 
Macrophages and microglial cells have different functions in the brain, but they have 
two main tasks which can be harmful if misregulated. One of these tasks is 
phagocytosis and engulfment of apoptotic material, debris or Aβ peptides. The other 
task is release of superoxide which can be directly toxic for neurons (Block et al. 2007; 
Bordt & Polster 2014). 
3.2.1 PolySia avDP20 Reduces Fibrillary Aβ1-42 and Debris Uptake in Macrophages 
Formation of Aβ plaques is one of the hallmarks of AD. It was shown that ITAM-bearing 
receptors might be included in the removal of Aβ [77][66]. SIGLEC-11 is an ITIM-
bearing receptor, which upon activation can counter regulate activation of ITAM 
receptors [58]. Here, we attempted to determine if polySia avDP20 is able to influence 
the function of iPSdM and macrophages through SIGLEC-11.  
IPSdM cell and THP-1 macrophage preparation and experimental procedures were 
done as mentioned in section 2.2.1. Ingestion of fibrillary Aβ1-42 into the iPSdMs and 
macrophages was observed by confocal microscopy and 3D-reconstruction (Fig 3-7 A 
and B). IPSdM cells were incubated with three different concentrations of polySia 
avDP20 (0.15 µM, 0.5 µM, and 1.5 µM). Among them, 0.5 µM (p=0.039) and 1.5 µM 
(p=0.015) of polySia avDP20 were able to significantly reduce fibrillary Aβ1-42 
phagocytosis (Fig 3-7 C). In detail, pre-incubation with 0.15 µM, 0.5 µM, and 1.5 µM 
polySia avDP20 reduced relative uptake of Aβ1-42 from 1 ± 0.12 to 0.76 ± 0.06 fold, 0.74 
± 0.06 fold, and 0.71 ± 0.06 fold, respectively (Fig 3-7 C). Similarly, THP-1 
macrophages were also incubated with three different concentrations of polySia 
avDP20 (0.15 µM, 0.5 µM, and 1.5 µM). Only 1.5 µM (p=0.003) polySia avDP20 was 
able to significantly reduce the relative fibrillary Aβ1-42 phagocytosis. In detail, pre-
incubation with 0.15 µM, 0.5 µM and 1.5 µM polySia avDP20 reduced uptake of Aβ1-42 
from 1 ± 0.08 to 0.94 ± 0.07 fold, 0.82 ± 0.02 fold, and 0.61 ± 0.06 fold, respectively (Fig 
3-7 D). 
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Figure 3-7: PolySia avDP20 reduced phagocytosis of fibrillary Aβ1-42 in iPSdM and THP-1 
macrophages. Representative Z-stack confocal images and 3D reconstruction of Aβ (red) and 
iPSdM labeled Iba1 (green, A) or macrophages labeled CD11b (green, B) immunostaining 
shows Aβ internalization. Scale bar: 20 µm. In iPSdM cells, 0.5 µM and 1.5 µM polySia avDP20 
pre-incubation reduced Aβ uptake (C). In THP-1 macrophages, 1.5 µM polySia avDP20 
decreased Aβ uptake by these cells (D). Data are presented as mean +/- SEM of at least three 
independent experiments and were analyzed using one-way ANOVA (Bonferroni). *, p<0.05; **, 
p<0.01. 
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Overexpression of siglec-e, which is an ITIM-bearing receptor in mouse, reduced neural 
debris engulfment into a microglial cell-line [68]. To explore the role of polySia avDP20 
in debris uptake via SIGLEC-11 receptor, iPSdM cells and THP-1 macrophages were 
prepared as mentioned in section 2.2.1. Uptake of neural debris into the iPSdM cells 
and macrophages was observed by confocal microscopy and 3D-reconstruction (Fig 3-8 
A and B). IPSdM cells were treated with three different concentrations of polySia 
avDP20. Only 1.5 µM (p=0.004) polySia avDP20 was able to significantly reduce 
phagocytosis of debris (Fig 3-8 C). In detail, pre-incubation with 0.15 µM, 0.5 µM, and 
1.5 µM polySia avDP20 reduced relative uptake of debris from 1 ± 0.07 in untreated 
group to 1.04 ± 0.06 fold, 0.78 ± 0.06 fold, and 0.68 ± 0.05 fold, respectively. THP-1 
macrophage responses to polySia avDP20 treatments were similar. Again, only 1.5 µM 
(p=0.007) polySia avDP20 was able to significantly reduce labeled debris phagocytosis 
(Fig 3-8 D). In detail, pre-incubation with 0.15 µM, 0.5 µM, and 1.5 µM polySia avDP20 
reduced relative uptake of debris by macrophages from 1 ± 0.06 to 0.95 ± 0.03 fold, 
0.84 ± 0.03 fold, and 0.7 ± 0.07 fold, respectively (Fig 3-8 D). 
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Figure 3-8: PolySia avDP20 reduced phagocytosis of labeled debris in iPSdM and 
macrophages. Representative Z-stack confocal images and 3D reconstruction of debris (red) 
and iPSdM labeled Iba1 (green, A) or macrophages labeled CD11b (green, B) immunostaining 
shows debris internalization. Scale bar: 20 µm. In iPSdM cells, 1.5 µM polySia avDP20 pre-
incubation reduced debris uptake (C). In THP-1 macrophages, 1.5 µM polySia avDP20 
decreased debris ingestion by these cells (D). Data are presented as mean +/- SEM of at least 
three independent experiments and were analyzed using one-way ANOVA (Bonferroni). *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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3.2.2 PolySia avDP20 Reduces Superoxide Production Triggered by Fibrillary Aβ1-
42 and Debris Uptake in iPSdM and Macrophages 
Aβ attachment to the cell surface of microglia results in activation of the tyrosine kinase 
Syk, which starts the assembly of a multi-subunit enzyme NADPH oxidase [78]. These 
microglial cells then release superoxides via the NADPH oxidase [79]. Accordingly, in 
this study the superoxide release from iPSdM cells or THP-1 macrophages after 
fibrillary Aβ1-42 stimulation was measured. In addition, the effect of polySia avDP20 was 
investigated. 
IPSdM cells and THP-1 macrophages were prepared for experiments as mentioned in 
section 2.2.2. Signal intensity quantification of DHE-labeled superoxide measurements 
showed that in iPSdM cells, fibrillary Aβ1-42 significantly increased the superoxide 
production compared to untreated cells (p=0.001; Fig 3-9 A). However, pre-incubation 
with 0.5 µM (p=0.02) and 1.5 µM (p=0.001) polySia avDP20 significantly prevented 
superoxide production (Fig 3-9 A). In detail, Aβ incubation increased the release of 
superoxides from 1 ± 0.06 in untreated cells to 1.4 ± 0.1 fold in Aβ treated cells. Pre-
incubation with 0.15 µM, 0.5 µM, and 1.5 µM PolySia avDP20 reduced the Aβ-caused 
superoxide release from 1.4 ± 0.1 to 1.18 ± 0.06 fold, 1.08 ± 0.07 fold, and 0.98 ± 0.04 
fold, respectively (Fig 3-9 A). 
Likewise, in THP-1 macrophages fibrillary Aβ1-42 significantly increased the superoxide 
production compared to untreated cells (p=0.004; Fig 3-9 B). Pre-incubation with 0.5 µM 
(p=0.048) and 1.5 µM (p=0.031) polySia avDP20 significantly prevented the superoxide 
production (Fig 3-9 B). In detail, Aβ incubation increased the superoxide release from 1 
± 0.05 in untreated cells to 1.43 ± 0.1 fold in Aβ treated cells. In detail, 0.15 µM, 0.5 µM, 
and 1.5 µM polySia avDP20 treatment reduced the Aβ induced superoxide release from 
1.43 ± 0.1 to 1.17 ± 0.04 fold, 1.10 ± 0.07 fold, and 1.08 ± 0.03 fold, respectively (Fig 3-
9 B). 
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Figure 3-9: PolySia avDP20 prevented the superoxide release induced by fibrillary Aβ1-42 
in iPSdM and macrophages. Measurments superoxide release by DHE staining showed that 
Aβ1-42 incubation significantly increased superoxide release in iPSdM (A) and macrophages (B). 
PolySia avDP20 pre-incubation prevented this increase both in iPSdM cells (A) and 
macrophages (B). Data are presented as mean +/- SEM of at least three independent 
experiments and were analyzed using one-way ANOVA (Bonferroni). *,p<0.05; **, p<0.01; 
***,p<0.001. 
 
Cellular debris can be recognized by ITAM-bearing receptors which leads then to 
superoxide release [80]. In an in vitro model, it has been shown that knockdown of 
siglec-e increased the superoxide release upon neural debris stimulation [68]. To test 
the stimulatory effect of cellular debris in the human in vitro system, superoxide release 
from iPSdM cells or THP-1 macrophages was measured after debris treatment. In 
addition, the effect of polySia avDP20 was investigated. 
IPSdM cells and THP-1 macrophages were prepared and experiments were done as 
mentioned in sectione 2.2.2. Signal intensity quantification of DHE-labeled superoxide 
measurements showed a significant increase in relative superoxide production in iPSdM 
cells after debris incubation compared to untreated cells (p<0.001; Fig 3-10 A). Pre-
incubation with 0.5 µM (p=0.047) and 1.5 µM (p<0.001) polySia avDP20 significantly 
prevented the relative superoxide production (Fig 3-10 A). In detail, debris incubation 
increased the superoxide release from 1 ± 0.05  in untreated cells to 1.45 ± 0.07 fold in 
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debris treated cells. PolySia avDP20 pre-incubation with 0.15 µM, 0.5 µM, and 1.5 µM 
reduced debris mediated superoxide release from 1.4 ± 0.07 to 1.21 ± 0.08 fold, 1.18 ± 
0.05 fold and 0.92 ± 0.04 fold, respectively (Fig 3-10 A). 
In THP-1 macrophages, debris treatment significantly increased the superoxide 
production compared to untreated cells as well (p=0.01; Fig 3-10 B). Pre-incubation with 
1.5 µM polySia avDP20 significantly prevented the superoxide production (p=0.01; Fig 
3-10 B). In detail, debris incubation increased relative superoxide release from 1 ± 0.09  
in untreated cells to 1.61 ± 0.1 fold in debris treated cells. 0.15 µM, 0.5 µM, and 1.5 µM 
polySia avDP20 reduced debris stimulated superoxide release from 1.61 ± 0.1 to 1.37 ± 
0.08 fold, 1.35 ± 0.08 fold, and 0.099 ± 0.1 fold, respectively (Fig 3-10 B). 
 
Figure 3-10: PolySia avDP20 prevented the superoxide release in debris stimulated 
iPSdM and macrophages. Measurments superoxide release by DHE staining showed that 
neural debris incubation significantly increased superoxide release in iPSdM (A) and 
macrophages (B). PolySia avDP20 pre-incubation hampered this raise in both iPSdM cells (A) 
and macrophages (B). Data are presented as mean +/- SEM of at least three independent 
experiments and were analyzed using one-way ANOVA (Bonferroni). *,p<0.05; **, p<0.01; 
***,p<0.001. 
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3.2.3 PolySia avDP20 Acts as Effectively as an Antioxidant 
A biological antioxidant is a substance that, at low concentration, prevents the oxidation 
of the substrate [81]. Already polySia avDP20 pre-incubation at 1.5 µM prevented 
superoxide release upon fibrillary Aβ1-42 and debris stimulation. Trolox and SOD1, which 
are well-known antioxidants, were chosen to compare the scavenging effect of 
antioxidants with polySia avDP20 to reduce oxidative stress.  
IPSdM cells and THP-1 macrophages were prepared and pre-incubated with 1.5 µM 
polySia avDP20, 60 U/ml SOD1 or 40 µM Trolox. Then, fibrillar Aβ1-42 or debris were 
added and the experiments were done as mentioned in section 2.2.2. Signal intensity 
quantification of DHE-labeled superoxide measurements showed in iPSdM cells the 
elevation in superoxide production upon fibrillary Aβ1-42 incubation (1.29 ± 0.05 fold) 
were reduced by both SOD1 (1.08 ± 0.05 fold; p=0.061;Fig 3-11 A) and Trolox (1.08 ± 
0.06 fold; p=0.074; Fig 3-11 A) pre-incubation. Comparably, this reducing effect was 
similar to polySia avDP20 pre-incubation (0.97 ± 0.05 fold; p<0.001; Fig 3-11 A). 
In THP-1 macrophages, the increased superoxide production upon fibrillary Aβ1-42 
incubation (1.42 ± 0.05 fold) was significantly prevented by both SOD1 (0.92 ± 0.1 fold; 
p=0.005; Fig 3-11 B) and Trolox (0.91 ± 0.1 fold; p=0.004; Fig 3-11 B) pre-incubation. 
Equivalently, this hampering effect was identical to polySia avDP20 pre-incubation (0.99 
± 0.02 fold; p=0.02; Fig 3-11 B). 
Results 
 
51 
 
 
Figure 3-11: PolySia avDP20 inhibitory effect upon Aβ1-42 stimulation is as strong as 
common antioxidants SOD1 and Trolox. Relative intensity of the superoxide-sensitive 
fluorescent dye measurments showed that SOD1 and Trolox pre-incubation reduced superoxide 
release upon fibrillary Aβ1-42 stimulation both in iPSdM cells (A) and THP-1 macrophages (B). 
The level of reduction was similar to polySia avDP20 pre-incubation. Data are presented as 
mean +/- SEM of at least three independent experiments and were analyzed using one-way 
ANOVA (Bonferroni). *,p<0.05; **, p<0.01; ***,p<0.001. 
 
To study the effect of neural debris, iPSdM cells and THP-1 macrophages were 
prepared for experiments as mentioned in section 2.2.2. In iPSdM, the elevation in 
superoxide production upon debris incubation (1.24 ± 0.05 fold) was significantly 
prevented by both SOD1 (0.85 ± 0.05 fold; p<0.001; Fig 3-12 A) and Trolox (0.96 ± 0.04 
fold; p=0.01; Fig 3-12 A) pre-incubation. The reducing effects of scavengers were as 
strong as polySia avDP20 pre-incubation (0.97 ± 0.04 fold; p=0.017; Fig 3-12 A). 
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Same experiments in THP-1 macrophages showed that the elevation in superoxide 
production upon cell debris incubation (1.4 ± 0.1 fold) significantly decreased by either 
SOD1 (0.86 ± 0.03 fold; p<0.001; Fig 3-12 B) or Trolox (0.93 ± 0.02 fold; p<0.001; Fig 3-
12 B) pre-incubation. PolySia avDP20 pre-incubation reduced superoxide release to the 
same level as scavengers (0.94 ± 0.03 fold; p<0.001; Fig 3-12 B). 
 
Figure 3-12: PolySia avDP20 inhibitory effect upon cell debris stimulation is similar to 
common antioxidants SOD1 and Trolox. Relative intensity of the superoxide-sensitive 
fluorescent dye measurements showed that SOD1 and Trolox pre-incubation reduced 
stimulatory production of superoxide upon cell debris addition both in iPSdM cells (A) and THP-
1 macrophages (B). The level of reduction is similar to polySia avDP20 pre-incubation. Data are 
presented as mean +/- SEM of at least three independent experiments and were analyzed using 
one-way ANOVA (Bonferroni). *, p<0.05; **, p<0.01; ***, p<0.001. 
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3.2.4 Knockdown of SIGLEC-11 Diminishes PolySia avDP20 Anti-Superoxide 
Effect 
The potential receptor of polySia avDP20 on iPSdM is SIGLEC-11. To confirm that 
polySia avDP20 has its inhibitory effects through SIGLEC-11 receptor, a knockdown 
experiment was performed. SIGLEC-11 knockdown cells were prepared as mentioned 
in section 2.4. Afterwards, DHE experiments were performed as mentioned in section 
2.2.2. In iPSdM cells which contained the control plasmid, Aβ1-42 stimulation increased 
superoxide release (1.19 +/- 0.01 fold; p=0.012; Fig 3-13) and polySia avDP20 pre-
incubation prevented this stimulation (0.93 +/- 0.03 fold; p<0.000; Fig 3-13). However, 
SIGLEC-11 knockdown abolished the repressing effects of polySia avDP20 on Aβ1-42 
induced superoxide production (1.24 +/- 0.06 fold; p<0.000; Fig 3-13).  
 
Figure 3-13: SIGLEC-11 knockdown eliminated the repressing effects of polySia avDP20. 
In cells which received a control plasmid, Aβ1-42 increased ROS production significantly 
compared to untreated cells and polySia avDP20 pre-incubation prevented this rise. Superoxide 
production in SIGLEC-11 knockdown cells compared to control cells increased and polySia 
avDP20 pre-incubation did not prevent this rise. Data are presented as mean +/- SEM of at 
least three independent experiments and were analyzed using one-way ANOVA. *, p<0.05; and 
***, p<0.001. 
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3.3 PolySia avDP20 Modulates iPSdM/Macrophage Function in Co-culture with 
Neurons 
Neher and colleagues showed that microglia actively uptake neurons if Aβ is present in 
the culture [39]. To investigate whether polySia avDP20 can hamper this phenomenon, 
first iPSdM-neuron and macrophage-neuron co-cultures were established. Then, the 
effect of adding polySia avDP20 to the co-culture systems was explored. 
3.3.1 Primitive Neural Stem Cells (pNSCs) 
To set up the co-culture system, it was necessary to obtain human neuronal cells. In 
2011, a relatively short and fast protocol was published, which used small inhibitory 
molecules to produce a homogenous culture of pNSCs from human embryonic stem 
cells [70]. In this study, the same protocol with small modifications was used to produce 
pNSCs from iPS cells as mentioned in section 2.1.1. pNSCs formation was confirmed 
by immunocytochemistry at passage 1 (Fig 3-14, A and B) and passage 10 (Fig 3-14, 
C-H). At passage 1, cells formed small colonies and strongly expressed NSC markers 
Nestin and ALP (Fig 3-14 A). Furthermore, the pluripotent stem cell marker Sox2 and 
ZO1 were also robustly expressed in these cells (Fig 3-14 B). By reaching a higher 
passage number (here 10), cells formed epithelial morphology and still expressed the 
NSC markers Nestin, Sox1, Sox2 and Pax6. Nestin (Fig 3-14 C) is a type VI 
intermediate filament protein, which is mainly expressed in dividing NSCs and is 
involved in the radial growth of the axons. Sox1 (Fig 3-14 D), Sox2 (Fig 3-14 E), and 
Pax6 (Fig 3-14 F) are transcription factors, which are necessary for maintaining self-
renewal and pluripotency of NSC. In addition, these cells were positive for the tight 
junction protein Zo1 (Fig 3-14, G) and cell proliferation marker Ki67 (Fig 3-14, H). 
pNSCs in our culture system were able to long-term self-renew over serial passages up 
to passage 30 on PLO + Fn coated dishes in the presence of hLIF, CHIR99021, and 
SB431542 inhibitory factors. 
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Figure 3-14: Characterization of pNSCs derived from iPS cells. pNSCs at passage 1 were 
positive for NSC markers such as nestin and ALP (A). Moreover, these cells expressed 
pluripotency marker Sox2 and rosette-type NSC marker ZO1 (B). Immunocytochemistry data 
showed that when pNSCs reached a higher passage number (here 10), they kept the 
expression of NSC markers Nestin, Sox1, Sox2 and Pax6 (C-F). In addition, they were positive 
for Zo1 and Ki67 (G-H). Scale bar: 50 μm. 
 
3.3.2 pNSCs Differentiation towards Mature Neurons 
To induce neuronal differentiation, pNSCs were cultured on PLO + Ln coated dishes 
with appropriate growth factors as mentioned in section 2.1.2. For neuronal 
characterization, immunocytochemistry with neuronal and non-neuronal markers was 
performed (Fig 3-15 and 3-16). Cultures were stained for glial markers olig2 (for 
oligodendrocyte; Fig 3-15 A), Iba1 (for microglial cells; Fig 3-15 B) and GFAP (for 
astrocyte; Fig 3-15 C) to investigate the neuronal culture’s purity. Immunocytochemistry 
data showed that the produced neuronal cultures did not contain any oligodendrocyte 
and microglial cells; however, they had GFAP positive cells (Fig 3-15).  
Neuronal cultures were stained for specific neuronal markers. Immunocytochemistry 
data showed that the neurons were positive for microtubule element of tubulin family (β-
tubulin-III), neurons intermediate filament (Neurofilament), microtubule-associated 
protein 2 (MAP2) and hexaribonucleotide binding protein-3 (NeuN), which is a neural 
nucleus marker (Fig 3-16, A-C). Developed neuronal cultures contained mostly 
catecholaminergic neurons (ChAT), GABAergic neurons (GABA) and a small population 
of tyrosine hydroxylase (TH) positive neurons (Fig 3-16, D-F). Staining with Ki67 
showed that even after two weeks of differentiation, the neuronal cultures still contained 
proliferating cells (Fig 3-16 G). 
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Fig 3-15: Purity of neuronal cell cultures. The developed neuronal cultures were stained for 
glial cells markers. The cultures were vacant of oligodendrocyes (olig-2, A) and microglial cells 
(Iba-1, B). There were always small populations of astrocytes in the neuronal cultures (GFAP, 
C). Negative controls contain no first antibodies (D). Scale bar: 50 μm. 
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Figure 3-16: Neuron specific markers expression. pNSCs differentiated into neurons with 
high efficiency. Immunocytochemistry data showed that neuronal cells were positive for β-
tubulin-III, Neurofilament, MAP2 and NeuN (A-C). The cultures contained different types of 
neurons such as ChAT, GABA, and TH-positive neurons (D-F). In addition, differentiated 
neuronal cultures had populations of proliferating cells (G). Scale bar: 50 μm. 
 
3.3.3 PolySia avDP20 Has no Effect on Metabolic Activity of Neurons  
To measure the metabolic activity of neurons, pNSC were seeded on PLO + Ln coated 
96-well plates. They were differentiated to neurons as mentioned in section 2.1.2. 
Neuronal cultures were treated for 24 hours with different concentrations (0.15 µM, 0.5 
µM, and 1.5 µM) of monoSia, triSia, hexaSia, and polySias (avDP20, avDP60, and 
avDP180). Afterwards, an MTT assay was performed as mentioned in section 2.5.4. 
MTT results showed that the metabolic activity of neurons did not change after 
treatment with different forms of Sias compared to the untreated control (Figure 3-17 A).  
Next, metabolic activities of neuronal cultures were checked with a wider concentration 
range of polySia avDP20 (from 5 nM to 5 mM). Once more, pNSC were seeded on PLO 
+ Ln coated 96-well plates as mentioned in section 2.1.2. After differentiation, neurons 
were treated for 24 hours with different concentrations of polySia avDP20. Then, an 
MTT assay was done as mentioned in section 2.5.4. MTT outcome showed that PolySia 
avDP20 did not reduce the metabolic activity of human neurons up to a concentration of 
5 mM. However, increased metabolic activity was observed at concentrations of 1.5 mM 
and 5 mM compared to the untreated group and all lower concentrations (p<0.001; Fig 
3-17 B). In detail, 1.5 mM and 5 mM polySia avDP20 increased the metabolic activity of 
neurons from 1 ± 0.03 to 2.5 ± 0.05 fold and 2.8 ± 0.05 fold, respectively (Fig 3-17 B). 
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Figure 3-17: Metabolic activity of neurons treated by Sias.  Metabolic activity measurements 
of neuronal cultures treated with different concentrations of monoSia, triSia, hexaSia, and 
polySias (avDP20, avDP60, and avDP180) after 24 hours showed no effect on cell viability of 
neurons (A). PolySia avDP20 treatment with different concentrations had no negative effect on 
neuronal cell viability. Even at 1.5 mM and 5 mM concentrations the cell viability was increased 
(B). Data are presented as mean +/- SEM of at least three independent experiments and were 
analyzed using one-way ANOVA (Bonferroni). ***, p<0.001 
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3.3.4 PolySia avDP20 Is Neuroprotective in iPSdM/Macrophage-Neuron Co-culture 
Systems against Aβ1-42 Mediated Toxicity 
It is known that fibrillar Aβ1-42 increases microglial phagocytosis function [82]. In 
addition, it induces uptake of living neurons by microglial cells through exposure of “eat 
me” signals on the neuronal cell surface [83]. To investigate whether polySia avDP20 
co-treatment is able to prevent the toxic effect of fibrillar Aβ1-42 co-incubation in co-
culture systems, two separate iPSdM-neuron and macrophage-neuron co-culture 
systems were established.  
For iPSdM-neuron co-culture system, pNSCs were seeded in 4-chamber slides and 
differentiated to mature neurons as mentioned in section 2.1.2. iPSdM-neuron co-
culture treatments were done as mentioned in section 2.1.6. Co-cultures were double 
immunostained with antibodies against β-tubulin III (neurons) and Iba1 (iPSdM; Fig 3-18 
A). Using neurite length as a neurotoxicity marker revealed that solely adding fibrillar 
Aβ1-42 to the culture system has no effect on relative neurite length (Fig 3-18 B). 
Alternatively, addition of the iPSdM in the presence of fibrillar Aβ1-42 significantly 
reduced relative neurite branch length (Fig 3-18 B). In detail, Aβ incubation with neurons 
slightly reduced branch length from 1 +/- 0.02 to 0.9 +/- 0.03 fold (p=0.104). However, 
incubation of Aβ with iPSdM-neuron co-culture further reduced the relative branch 
length to 0.64 +/- 0.03 fold (p<0.001 vs neurons and neurons plus Aβ; Fig 3-18 B). This 
reduction supports the idea of toxic fibrillar Aβ effect mediated by microglial cells. 
Incubation with 1.5 µM PolySia avDP20 protected branches from the toxic effect of 
fibrillar Aβ1-42 activated iPSdM cells (0.82 +/- 0.03 fold; p=0.002; Fig 3-18 A and C). 
Furthermore, incubation with Trolox protected branches from the toxic effect of fibrillar 
Aβ1-42 activated iPSdM in co-culture system, too (1.02 +/- 0.03 fold; p<0.001; Fig 3-18 
C).  
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Figure 3-18: Neuroprotective effect of polySia avDP20 in Aβ-activated iPSdM-neuron co-
cultures. Representive immunocytochemistry images of neuron-iPSdM co-culture in the 
presence of Aβ with (right picture) or without (left picture) polySia avDP20 (A). Relative neurite 
length was shorter in the presence of Aβ in neuron-iPSdM co-culture (B). Relative neurite length 
was protected against Aβ if polySia avDP20 was present in the culture system. Trolox 
prevented neurotoxic effect in all different co-culture conditions (C). Data are presented as 
mean +/- SEM of at least three independent experiments and were analyzed using one-way 
ANOVA. **, p<0.01; and ***, p<0.001. Scale bar: 50 µm. 
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In neuron-macrophage co-culture system, pNSCs were differentiated to mature neurons 
as mentioned in section 2.1.2. Macrophage-neuron experiments were done as 
mentioned in section 2.1.6. Analysis of the neurite length showed the same effect as in 
the iPSdM-neuron co-culture. Co-cultures were double immunostained with antibodies 
against Neurofilament (neurons) and CD11b (macrophages ;Fig 3-19 A). Addition of 
fibrillar Aβ1-42 to the macrophage-neuron co-culture system had no effect on relative 
neurite length (Fig 3-19 B). Although, inclusion of macrophages in the presence of 
fibrillar Aβ1-42 significantly reduced the relative neurite branch length (Fig 3-19 B). In 
detail, Aβ incubation with neurons reduced the branch length from 1 +/- 0.02 to 0.82 +/- 
0.14 fold (p=0.233). Incubation of Aβ with macrophage-neuron co-culture further 
decreased relative length of branches to 0.57 +/- 0.05 fold (p=0.012; Fig 3-19 B). As 
expected, polySia avDP20 and Trolox incubation protected neuronal branches from the 
toxic effects of fibrillar Aβ1-42 activated macrophages in co-culture systems (0.9 +/- 0.05 
fold, p=0.020; 0.9 +/- 0.09 fold, p=0.025, respectively; Fig 3-19 A and C).  
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Figure 3-19: Neuroprotective effect of polySia avDP20 in Aβ-activated macrophage-
neuron co-culture. Representive immunocytochemistry images of neuron-macrophages co-
culture in the presence of Aβ with (right picture) or without (left picture) polySia avDP20 (A). 
Relative neurite length was shorter in the presence of Aβ in neuron-macrophage co-culture 
system (B). Addition of polySia avDP20 protected relative neurite length against reducing 
effects of Aβ in culture system. Furthermore, Trolox prevented the neurotoxic effect in all 
different co-culture conditions (C). Data are presented as mean +/- SEM of at least three 
independent experiments and were analyzed using one-way ANOVA. *, p<0.05. Scale bar: 50 
µm. 
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3.3.5 PolySia avDP20 Is Neuroprotective in iPSdM/Macrophage-Neuron Co-culture 
Systems against LPS Mediated Toxicity 
LPS activates the phagocytosis function of microglia/macrophages indirectly and 
increases release of ROS, which is directly toxic to neurons [84]. Activation of SIGLEC-
11 in transduced murine microglial cells, decreased the gene transcription of LPS-
stimulated pro-inflammatory mediators [69]. To investigate whether polySia avDP20 co-
treatment has any effect on LPS-activated iPSdM/macrophages in co-culture systems, 
iPSdM-neuron and macrophage-neuron co-culture systems were established.  
Neuron-iPSdM co-culture systems were prepared as mentioned in section 2.1.2 and 
experiments were done as mentioned in section 2.1.6. Co-cultures were double 
immunostained with antibodies against β-tubulin III (neurons) and Iba1 (iPSdM; Fig 3-20 
A). Analysis of neurite lengths revealed that addition of both normal iPSdM and LPS-
activated iPSdM to the neural culture system decreased relative neurite length. 
However, LPS-activated iPSdM cells significantly reduced relative neurite branches 
length compared to normal iPSdM cells (p=0.04; Fig 3-20 B). In detail, normal iPSdM 
incubation with neurons reduced branch length from 1 +/- 0.03 to 0.76 +/- 0.01 fold 
(p=0.003; Fig 3-20 B), and LPS-activated iPSdM incubation further reduced relative 
branch length to 0.64 +/- 0.02 fold (p<0.001; Fig 3-20 B). To explore the effect of 
polySia avDP20 in this system, 1.5 µM polySia avDP20 was incubated with LPS-
activated iPSdM cells. Data show that addition of polySia avDP20 protected neurite 
branches from the toxic effect of LPS-activated iPSdM cells in co-culture systems (0.91 
+/- 0.02 fold; p=0.001; Fig 3-20 A and B).  
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Figure 3-20: Neuroprotective effect of polySia avDP20 in LPS-activated iPSdM-neuron co-
cultures. Representive immunocytochemistry images of neuron-iPSdM co-culture in presence 
of normal iPSdM (upper picture) or LPS-activated iPSdMs (lower picture) with (right pictures) or 
without (left pictures) polySia avDP20 (A). Relative neurite lengths were shorter in presence of 
both normal iPSdM and LPS-activated iPSdM cells. However, this reduction was more severe in 
the presence of LPS-activated iPSdM cells. PolySia avDP20 incubation protected neurons from 
LPS-activated iPSdM cells (B). Data are presented as mean +/- SEM of at least three 
independent experiments and were analyzed using one-way ANOVA. *, p<0.05; **, p<0.01; and 
***, p<0.001. Scale bar: 50 µm. 
As mentioned before, neuron-macrophage co-culture systems were prepared. Co-
cultures were double immunostained with antibodies against Neurofilament (neurons) 
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and CD11b (macrophages; Fig 3-21 A). Analysis of neurite length demonstrated that 
inclusion of both normal macrophages and LPS-activated macrophages to the neural 
culture system reduced relative neurite lengths. In detail, THP-1 macrophage incubation 
with neurons reduced branch length from 1 +/- 0.05 to 0.55 +/- 0.02 fold (p<0.001; Fig 3-
21 B), and LPS-activated THP-1 macrophages incubation further reduced relative 
branch length to 0.05 +/- 0.01 fold (p<0.001; Fig 3-21 B). PolySia avDP20 incubation in 
this system, protected neurite branches from the toxic effects of LPS-activated 
macrophages in co-culture systems (0.69 +/- 0.02 fold; p=0.03; Fig 3-21 A and B).  
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Figure 3-21: Neuroprotective effect of polySia avDP20 in LPS-activated macrophage-
neuron co-culture. Representive immunocytochemistry images of neuron-macrophage co-
culture in presence of normal macrophages (upper pictures) or LPS-activated macrophages 
(lower pictures) with (right pictures) or without (left pictures) polySia avDP20 (A). Relative 
neurite length was shorter in the presence of both normal macrophages and LPS-activated 
macrophages. PolySia avDP20 incubation partly protected neurons from LPS-activated 
macrophages (B). Data are presented as mean +/- SEM of at least three independent 
experiments and were analyzed using one-way ANOVA. *, p<0.05 and ***, p<0.001. Scale bar: 
50 µm. 
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4 Discussion 
A contribution of activated microglial cells and an altered neuronal glycocalyx on 
progression of AD has been reported by many studies [68], [69]. Sia molecules are 
abundant on the outermost surface of intact glycocalyx. These molecules are 
recognized by SIGLEC receptors [80]. SIGLEC-11 is specifically expressed in resident 
tissue macrophages including brain microglial cells [85]. To determine the optimal 
length of Sia as a SIGLEC-11 ligand, this study used different lengths of oligoSia and 
polySia in in vitro systems and found polySia avDP20 to be a potential ligand for 
SIGLEC-11. Accumulation of extracellular Aβ plaques and appearance of inflammatory 
activated microglial cells are hallmarks of AD [86]. One of the mechanisms by which Aβ 
can activate microglial cells is through several scavenger receptors that could also 
signal through the ITAM-carrying adaptor molecule TYROBP/DAP12. This leads to 
activation of downstream signaling pathways and results in the increased phagocytosis 
function of microglia and/or release of ROS that is directly toxic to neurons [66], [74]. 
Within this study, the role and involvement of microglial SIGLEC-11, an ITIM-carrying 
receptor, in counter-regulation of Aβ activatory effects was investigated. This study 
reveals new evidence concerning the role of polySia molecules in modulating microglial 
functions in brain and toward neurons. In addition, the results shed light on the potential 
capacity of polySia avDP20 to be further investigated as a drug for neurodegenerative 
diseases.   
 
4.1 PolySia avDP20 Is the Potential Ligand for SIGLEC-11 
SIGLEC-11 was first identified as a human microglial specific receptor in 2005 and from 
that time investigations tried to detect the possible ligand for it in the brain [56]. In the 
first part of this thesis, SIGLEC-11 expression on cell lines was explored and the effect 
of different lengths of Sias was investigated. Results showed that monoSia and 
oligoSias did not prevent ROS production from Aβ activated cells. However, polySia 
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avDP20 and avDP60 were able to prevent ROS production. Measuring metabolic 
activity of cells showed that polySia avDP60 had negative effect on cell viability. No 
change in cell survival was observed in polySia avDP20 treated cells. In addition, ELISA 
data showed that there was a direct binding between polySia avDP20 and rhSIGLEC-
11/Fc protein.  
4.1.1 SIGLEC-11 Expression 
As mentioned before, SIGLEC-11 is a member of CD33-related SIGLECs. SIGLECs in 
innate immune cells can recognize both self-endogenous and invading pathogen 
sialylations. According to recent data, there are variations in expression of SIGLECs on 
circulatory blood immune cells (monocytes, leukocytes, and lymphocytes) compared to 
tissue macrophages and neutrophils [87], [88]. SIGLEC-3, -5 and -9 are highly 
expressing on monocytes. SIGLEC-3 is also highly expressed in tissue macrophages, 
while SIGLEC-5 is not expressed and SIGLEC-9 is only expressed on a subset 
population [87]. In this study, data show that SIGLEC-11 is expressed on iPSdM cells, 
THP-1 monocytes, and macrophages both on mRNA and protein levels. This 
expression makes these cells proper models to find out the potential ligand for SIGLEC-
11 receptor. In addition, as it was expected, expression level of SIGLEC-11 is higher in 
THP-1 macrophages compared to monocytes. 
4.1.2 OligoSia and PolySia as a Ligand 
The glycocalyx is a dense complex array of sugar units which are attached to the lipids 
and proteins on the cell surface [89]. The outermost ends of these sugar units are 
decorated with Sias, which can have diverse conformations due to their length [90]. 
Commonly, Sia units are able to form oligo/poly structures and accordingly are 
classified as diSia (DP=2), oligoSia (DP=3-7) and polySia (DP>8) [46]. Comparably, to 
determine structure’s effect on function, distinct lengths of Sia were used in this study: 
monoSia, oligoSia (with DP3 and DP6), and polySia (with DP20, DP60, and DP180).  
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In mammals, a wide number of gangliosides and glycoproteins are modified by 
oligoSias (mainly with DP=3-7). This change enables them to be recognized by 
SIGLEC-7 or SIGLEC-11 which prefer α 2→8 linked Sias [46], [91]. Both SIGLEC-7 and 
SIGLEC-11 are ITIM bearing/inhibitory receptors and are involved in regulation of innate 
immune responses. SIGLEC-7 is expressed on natural killer (NK) cells, monocytes, 
basophils, and mast cells and shows a preference for α 2→8 linked diSias on 
gangliosides [92], [93]. SIGLEC-11 is expressed in a broad range of tissue 
macrophages such as Kupffer cells in liver, microglial cells in brain, perifollicular cells in 
spleen, and lamina propria macrophages in intestine and shows binding specificity to α 
2→8 linked Sias [94]. However, unlike SIGLEC-7, SIGLEC-11 does not show clear 
binding to gangliosides carrying α 2→8 linked Sias. According to the literature, it was 
clear that SIGLEC-11 prefers α 2→8 linked structures to bind, but the length of Sia 
which has a great effect on conformation of the molecule was not clear. In this thesis, 
diverse lengths of small Sia molecules were used (monoSia, oligoSia DP3, oligoSia 
DP6) and their influence on iPSdM cell response was explored. As expected, cell 
treatment by monoSia and oligoSias were not adequate to prevent the stimulatory effect 
of Aβ on ROS production.  
PolySia is a homopolymer of α 2→8 linked Sias which is added to the membrane 
proteins as a posttranslational modification [91]. In contrast to oligoSias, polySia are 
added only to some specific proteins which are mainly expressed in the CNS or immune 
cell network. These proteins consist of neural cell adhesion molecule (NCAM/CD56), 
synaptic cell adhesion molecule (SynCAM1), CD36, neuropilin2 (NRP-2), α-subunit of 
the voltage-gated sodium channel and autopolysialylation of sialyltransferases that 
polymerize polySia (ST8 SiaII, ST8 SiaIV) [95]–[97]. PolySias play an important role in 
cell adhesion, migration, and cytokine response of immune cells. Studies showed that 
polySias are expressed on mice bone marrow (BM) neutrophils and monocytes, but 
these cells gradually lose the polySia expression while they migrate toward 
inflammation sites [98]. In human system, monocyte-derived DC and NK cells also 
regulate polySia expression according to the activation state. In this context, cells 
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express less polySia as they mature [97], [99]. In total, it seems that upon arrival of 
blood immune cells to the target tissue, the self polySia expression reduces but the 
expression of self SIGLECs increases. PolySia are recognized by SIGLEC receptors 
and, as mentiond before, SIGLEC-11 is specifically expressed on microglial cells. This 
expression makes SIGLEC-11 a potential receptor for polySia, which is highly 
expressed on neuronal cells. In this thesis, to explore this possibility, iPSdM cells were 
treated with different lengths of polySia (polySia avDP20, avDP60, and avDP180). 
Results indeed confirmed that polySia avDP20 and avDP60 treatment prevented ROS 
release from Aβ-stimulated iPSdM cells. However, polySia avDP60 showed a negative 
effect on metabolic activity of iPSdM cells.  
4.1.3 PolySia avDP20 Binds to SIGLEC-11 
SIGLEC-11-modulated microglial cell behavior in an in vitro co-culture system was 
dependent on neuronal polySia residues, but independent of microglial polySia itself 
[69]. This thesis shows that polySia avDP20 can modify the response of iPSdM cells 
and THP-1 macrophages towards Aβ. ELISA data showed that there is a direct binding 
between polySia avDP20 and rhSIGLEC-11-Fc protein, but dextran (a branched glucan 
with different lengths but same molecular weight) did not attach. In addition, SIGLEC-11 
knockdown was enough to abolish the averting effect of polySia avDP20 treatment both 
in iPSdM cells and THP-1 macrophages.  
 
4.2 PolySia avDP20 Changes iPSdM Cell and THP-1 Macrophage Function  
Microglia, the brain inspectors, like other immune cells have a specific role to survey 
brain environment. Aβ deposition is one the main signs in AD progression and its total 
amount is equal to its production minus its removal. This indicates the crucial role of 
clearance mechanisms and reveals the importance of microglial cells [100]. 
Accumulation of Aβ damaged neurons and induced apoptosis cause debris production, 
which should be cleared by microglial cells. In this situation, microglial cells remove Aβ 
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and debris by inflammation associated phagocytosis, which is linked with the release of 
ROS in pathological conditions like AD [74]. In the second part of this thesis, the role of 
SIGLEC-11 activation by polySia avDP20 in face of Aβ and apoptotic material was 
investigated. Results demonstrated that polySia avDP20 incubation reduced uptake of 
both Aβ and debris by iPSdM cells and THP-1 macrophages. Moreover, polySia 
avDP20 prevented the ROS production towards stimulants. This prevention was similar 
to Trolox and SOD1 effects in blocking ROS production upon phagocytes stimulations. 
4.2.1 PolySia avDP20 Reduces Phagocytosis Function 
Phagocytosis is one of the normal functions of microglial cells as phagocytes. 
Phagocytosis occurs either by homeostatic phagocytosis or by inflammation-associated 
phagocytosis. Fibrilar Aβ1-42 and debris are recognized by danger-associated molecular 
pattern (DAMPs), which increase microglial inflammation-triggered phagocytosis activity 
and leads to release of TNF-α, IL-β or ROS and directly harm neurons [82], [101], [102]. 
Simultaneously, as fast as plaques or apoptotic materials are recognized, several anti-
inflammatory responses are activated to maintain homeostasis. Therefore, negative 
signals are important to balance phagocytic activity [103]. 
Microglial function is controlled via diverse sets of receptors on the cell surface, and Aβ 
can be recognized by some of these surface receptors. Part of these receptors are 
activatory receptors such as TREM2 or SIRPβ1, which signal via TYROBP/DAP12 
(bearing ITAM motif in intracellular part) [104]. Upon activation, these receptors 
phosphorylate downstream proteins and activate signaling pathways [66], [67], [77]. 
SIRPβ1 knockdown reduced uptake of Aβ and apoptotic neural material in mice primary 
microglial cells [66]. Siglec-h is another example which is expressesd on mouse 
microglial cells and signals via TYROBP/DAP12. Induction of this receptor by Siglec-h 
specific antibody-coated beads increased phagocytosis function in the microglia line, 
while knockdown of this receptor neutralized bead uptake [105]. 
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On the other side, the function of ITAM carrying receptors is counter-regulated by 
inhibitory receptors such as SIGLEC receptors. Most SIGLECs carry an ITIM motif in 
their intracellular part and, by ligand attachment, antagonize the kinase activation signal 
and hamper signaling pathways [58]. ITIM carrying receptors are negative regulators of 
immune response and have an important role to prevent the harmful consequences of 
inflammation [106]. Aggregated Aβ covered by sialylated glycolipids and glycoproteins 
are identified by microglial SIGLECs and are not removed by these cells [60]. SIGLEC-3 
(an ITIM carrying receptor) positive microglial cells increase in AD patients and there is 
an association between Aβ aggregation and the number of SIGLEC-3 positive cells 
[107]. Moreover, in mice microglial culture systems, elevated SIGLEC-3 levels inhibited 
Aβ uptake; while reduced SIGLEC-3 was enough to increase Aβ phagocytosis and Sia 
was necessary to modulate this function [107]. Thus, it seems that ITAM and ITIM 
receptors are counter-regulating Aβ clearance mechanisms. In this thesis, polySia 
avDP20 incubation reduced Aβ uptake in SIGLEC-11 expressing iPSdM cells and THP-
1 macrophages, which is in line with current literatures. 
In most neurodegenerative diseases the presence of debris in the brain parenchyma is 
increased [108]. Removal of debris is essential for effective regeneration, while their 
uptake may lead to inflammation. This could result in neuronal antigen presentation, 
which activates autoimmune responses [108], [109]. Several studies show that 
activation of ITIM-carrying receptors lead to reduced debris phagocytosis. In mice 
system, siglec-e (an ITIM carrying receptor) overexpression reduced uptake of neural 
debris into microglial cells, while siglec-e knockdown increased debris uptake [68]. In 
another study, murine microglial cells transduced with SIGLEC-11 exhibited less uptake 
of apoptotic neural material, while microglial cells that received a control vector had 
more capacity for apoptotic material uptake [69]. Accordingly, in this thesis polySia 
avDP20 incubation reduced debris uptake in SIGLEC-11 expressing iPSdM cells and 
THP-1 macrophages. 
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In total, SIGLEC receptors do not change the homeostatic phagocytosis but they 
efficiently reduce inflammatory-mediated phagocytosis of  fibrilar Aβ1-42 or debris.  
4.2.2 PolySia avDP20 Reduces ROS Production  
The direct consequence of microglial activation by debris and Aβ is the respiratory burst 
and release of ROS, which contributed to neuronal damage [110]. The source of ROS is 
mainly microglial NADPH oxidase activity. NADPH oxidase consists of two membrane 
components (p22phox and gp91phox) and four cytosolic components (p47phox, p67phox, 
p40phox, and small G-protein Rac). Upon stimulus activation of a microglia/macrophage 
cell, the cytosolic subunits assemble with membrane components and initiate 
superoxide (O2̄ ) production [78]. In detail, Aβ is recognized by surface receptors, which 
are able to recruit Src-family of Tyr kinase. Then, phosphorylation and activation of Vav 
guanine nucleotide exchange factor (GEF) activity results in GDP to GTP exchange on 
Rac GTPase. This exchange leads to assembly of subunits of NADPH oxidase and 
release of ROS [111][78]. Engagement of tyrosine kinase Syk and membrane NADPH 
oxidase in response to microglial stimulation is necessary since pretreatment with 
piceatannol (inhibitor of Syk) significantly reduce Aβ stimulated tyrosine phosphorylation 
[73], [112]. In addition, using gp91ds-tat (NADPH oxidase inhibitory peptide) and 
gp91phox -/- mice showed that Aβ stimulated ROS release was revoked [73], [112]. 
Primary culture of rat microglia and THP-1 monocyte incubation with Aβ initiated 
superoxide production, which was inhibited by SOD treatment [73]. In addition, BV2 
microglial cell exposure to fibrillary Aβ1-42 significantly increased ROS production via 
NADPH oxidase activity [74]. Equally, in this thesis treatment with fibrillary Aβ increased 
ROS production in iPSdM cells and THP-1 macrophages, while polySia avDP20 
incubation prevented ROS release upon Aβ inclusion. 
If apoptotic material is not removed properly by phagocytosis, then the membrane 
integrity in apoptotic compartment vanishes over time and they will become necrotic 
substances [113]. In neonatal cerebellum sections, superoxide produced by microglial 
cells was the main source of Purkinje cell death [114]. In another model of neonatal 
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stroke, removal of apoptotic neurons by activated microglial cells were limited. However, 
even this slight removal was protective since depletion of microglial cells before stroke 
increased accumulation of inflammatory mediators like superoxide [115]. In an in vitro 
study, Siglec-e overexpression in microglial cells reduced ROS production upon debris 
stimulation, while knockdown of Siglec-e led to increased ROS release [68]. In the same 
manner, in this thesis debris treatment leads to increase ROS production in iPSdM cells 
and THP-1 macrophages, albeit polySia avDP20 incubation prevented this rise. 
4.2.3 PolySia avDP20 Inhibits ROS Production as Effectively as Antioxidants 
As mentioned, oxidative stress in one of the main sources of neuronal damage. ROS 
such as superoxide (O2̄ ) and hydrogen peroxide (H2O2) are mainly produced by 
dysfunction of mitochondrial respiratory chain; however, membrane NADPH oxidase 
also produce ROS [116]. O2̄ can quickly react with nitric oxide (NO) and produce 
peroxynitrite; as well H2O2 can produce hydroxyl radicals (•HO). Both peroxynitrite and 
hydroxyl radicals are highly toxic and damage biological molecules’ functions [117]. The 
brain is responsible for about 20% of basal body O2 consumption and any interference 
in the oxygen respiratory chain cause huge damage to neurons (reviewed in Halliwell 
2006). Therefore, substances that are able to reduce these highly reactive oxygen 
radicals can be considered as a potential therapeutic agent in neurodegenerative 
processes. Trolox is a water-soluble analog of vitamin E, which inhibits lipid 
peroxidation by scavenging peroxyl radicals and is used commonly as an antioxidant in 
biological experiments to scavenge ROS [118]. SOD1 is one of the three human 
superoxide dismutases enzymes. SOD1 catalyzes O2 ̄ to H2O2, which is then later 
broken down by catalase [119]. Siglec-e is a negative regulator of ROS released by 
mouse microglial cells [68]. Trolox kept neurite length in the normal range when 
neurons were co-cultured with Siglec-e knockdown microglial cells [68]. In this thesis, 
both Trolox and SOD1 treatments prevented the phagocytosis associated ROS release 
from iPSdM cells and THP-1 macrophages. In the same way, treatment with polySia 
avDP20 prevented release of ROS upon Aβ and debris challenge via SIGLEC-11 ITIM 
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signaling, since knockdown of this receptor was enough to abolish polySia avDP20 
effect. Thus, in total polySia avDP20 like Trolox and SOD1 is able to keep ROS release 
at the basic level in in vitro cultures.  
 
4.3 PolySia avDP20 Has Neuroprotective Function 
Neurons, as the central components of the CNS, are in close relation with microglial 
cells. Presence of Aβ or LPS in brain parenchyma induces immune responses by 
microglial cells. Microglia, by recognition of these stimuli, become active and produce 
neurotoxic pro-inflammatory factors. They may become overactive by damaged 
neurons, harming adjacent neurons [110]. In the third part of this thesis, neurons 
differentiated from iPS cells to establish a co-culture system and the effects of diverse 
polySia avDP20 concentrations were explored. Afterwards, the role of polySia avDP20 
treatment in face of Aβ and LPS stimulation in neuron-iPSdM or neuron-macrophage 
co-culture systems were investigated. Results show that polySia avDP20 incubation 
reduced neurotoxicity effects of both Aβ and LPS mediated by iPSdM cells or THP-1 
macrophages. Moreover, this protective effect towards stimulants was similar to Trolox 
incubation, however, it was not as strong.  
4.3.1 Human Neuron Culture from iPS Cells 
To establish a human co-culture system, a stable NSC line was necessary to constantly 
have neurons in culture. pNSCs were obtained from iPS cells according to a short 
protocol which initially used small inhibitory molecules to get pNSCs from human ES 
cells [70]. As mentioned before, four small inhibitory molecules (hLIF, CHIR99021, 
SB431542 and Compound E) were used to differentiate pNSCs from iPS cells. HLIF 
already has been shown to be essential for maintaining pluripotency [120]. CHIR99021 
inhibits GSK-3β, which is a main component in the canonical Wnt pathway with a 
negative role in neuronal induction. Thus, inhibition of GSK-3β activates the canonical 
Wnt pathway and increases neural induction [121]. SB431542 inhibits mesodermal 
Discussions 
 
78 
 
induction and helps the cell culture to go towards ectodermal fate [122]. Compound E 
aids to stop cell differentiation [70] . All these factors help to differentiate pNSCs from 
iPS cells. pNSCs express NSC markers nestin, Pax6, Sox1 and Sox2. Nestin is a type 
VI intermediate filament protein which is expressed by uncommitted neural progenitor 
cells and is extensively expressed by our pNSCs [123]. Pax6 has been shown to 
increase neurogenesis from human fetal striatal NSCs. In addition, Pax6 and Sox2 are 
required for maintaining progenitor proliferative capacity of NSCs [124], [125]. pNSCs 
were also positive for Ki67, so they kept their proliferative phenotype.  
pNSCs easily differentiate into neurons in the presence of BDNF and GDNF in 2 weeks. 
The resulting neurons were highly positive for neuronal markers NeuN, β-tubulin-III, 
neurofilament and MAP2. They have been positive for the neurotransmitters ChAT and 
GABA, but only few cells have been positive for the dopaminergic marker TH [126].  
4.3.2 PolySia avDP20 Is Neurotrophic  
Between different candidate molecules who have roles in neuronal plasticity, neural cell 
adhesion molecule (NCAM) and its attached polySia chains have received most 
attention. NCAM according to it molecular weight is present in four main isoforms 
(NCAM-180, NCAM-140, NCAM-120 and soluble NCAM) with one of the main post-
translational modifications, which is the addition of a linear homopolymer of α 2→8 
linked Sias [127]. The expression of polySia-NCAM is highly regulated. Peak expression 
occurs during the early stages of brain development, followed by a continuous 
reduction, which leads to its regional expression in three types of neurons in adults 
brains. The first population is located in layer II of the paleocortex, which mostly lacks 
NeuN expression (immature neurons) [48]. To the second population belong mature 
NeuN positive inhibitory interneurons located in cortical areas such as prefrontal cortex, 
hippocampus, and amygdala [48]. The third population includes differentiated neurons 
with polySia negative soma but polySia positive neuritis, like hippocampus mossy fibers 
or pyramidal cells of CA1 region [48]. The most defining character of polySia is related 
to its polyanionic nature, which gives this molecule the anti-adhesive feature. This 
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feature enables it to has an important role in cell-cell and cell-matrix interactions [46]. 
Polysialyltransferases (PSTs) are key regulators of polySia synthesis in mammalian 
cells [128]. Due to this fact, many experiments have been done in recent years to 
examine polySia’s function on neuronal cell behavior by changing the expression of 
PSTs. Motor neurons derived from mouse ES cells when transduced to express more 
PST (results in more polySia expression) showed increased survival and neurite 
outgrowth towards denervated muscles [129]. ES cell-derived dopaminergic neurons 
transduced with a lentiviral-expressing PST and grafted into a hemiparkinsonian mouse 
model showed increased survival without phenotypic change and neurite outgrowth 
[130]. Furthermore, increased PST expression resulted in complete recovery in mice 
with correction of behavioral impairment [130]. In this thesis, treatment of iPS-derived 
neuronal cells with different lengths and concentrations of Sia, oligoSia and polySia had 
no negative effect on metabolic activity of neurons. Moreover, treatment with polySia 
avDP20 improved neuronal metabolic activity in a concentration dependent manner. 
4.3.3 PolySia avDP20 Effect in Aβ Stimulated iPSdM/macrophage-neuron Co-
culture Systems 
Phagocytosis and polySia: In a healthy situation, microglial cells are in resting state. 
This means that their soma stay stable, but their processes are motile and continuously 
survey their microenvironment [103]. Any alteration in normal conditions, which is 
sensed by microglia, impairs microglial homeostasis and damages neurons [103]. 
Uptake of neurons occurs by two mechanisms: phagocytosis, which is removal of 
apoptotic or necrotic neurons that express eat me signals, and phagoptosis, which is 
removal of live neurons that transiently express eat me signals [84]. One of the 
important eat me signals on the neuronal surface is the appearance of PS, which is 
normally located in the inner leaflet of the cell membrane. Its exposure on the outside of 
the neuron can be increased by Aβ1-42 incubation [131]. PS is recognized by opsonins 
like milk fat globule EGF factor 8 (MFG-E8) and then bound to the vitronectin receptor 
on the microglial surface or directly to another microglial receptor called brain-specific 
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angiogenesis inhibitor1 (BAL1) [84]. In a rat neuron-microglia co-culture system, low 
concentration of Aβ induced neuronal loss without increasing apoptosis or necrosis, 
further investigation showed that neuronal loss was mediated by the microglial 
phagocytosis function, which was boosted by Aβ [83]. Blocking PS or inhibiting 
microglial phagocytosis was enough to save neurons [83]. Later on, the same group 
showed that Aβ induced peroxynitrite release from microglia forced neurons to show PS 
eat me signal. Then, this neurons were taken up by phagoptosis through the PS-MFG-
E8-vitronectin pathway [39]. Besides, treatment with peroxynitrite scavenger or 
vitronectin receptor antagonist was enough to inhibit neuronal loss [39]. In line with this 
literature, in the thesis at hand treatment of neuronal cultures with Aβ alone showed no 
difference in neurite length. However, co-incubation of iPSdM-neuron or macrophage-
neuron co-culture systems with Aβ showed reduced neurite branches length. Another 
eat me signal is the removal of the Sia cap from surface neuronal glycoproteins [126]. 
The altered glycocalyx followed by C1q opsonization, which recognizes by mouse 
microglial CR3 or human macrophage CR3; although, in both situations intact neurites 
with sialylated glycoproteins remain undamaged [126], [132]. Thus, it seems that neurite 
sialylation is an inhibitory signal for microglial cells and macrophages. Indeed, there are 
some don’t eat me signals on neuronal surface like CD47 and sialylated glycoproteins 
that are recognized by microglial receptors SIRP1α and SIGLEC-11 to prevent 
phagocytosis [84]. In a mouse neuron-microglia co-culture system, intact polySia 
expressing neuronal cultures were incubated with SIGLEC-11 vector transduced 
microglial cells [69]. This culture showed higher neurite density compare to incubation 
with control vector transduced microglia. However, in polySia removed neuronal culture 
this outcome was not observed [69]. In line with this observations, here the toxic effect 
of Aβ incubation in iPSdM-neuron and macrophage-neuron co-cultures was eliminated 
by co-treatment with polySia avDP20. 
ROS and polySia: Another consequence of microglial cell activation by Aβ is ROS 
release, which is directly toxic to neurons in co-culture experiments [79]. APP 
overexpression alone was not toxic for APP-expressing-neuroblastoma cells; despite 
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the fact that co-culture of these neurons with microglial cells leads to enormous cell 
death via ROS release by microglial cells [133]. Aβ incubation can induce NADPH-
oxidase assembly in rat primary microglial cells and release of ROS in a dose 
dependent manner [134]. Nevertheless, melatonin as an antioxidant inhibited 
superoxide release by impairing the assembly of NADPH oxidase in these microglial 
cells [134]. In this thesis, incubation of co-cultures with Trolox was able to keep neurite 
length in Aβ treated iPSdM/macrophage-neuron neuronal cultures as in untreated 
neuronal cultures. Incubation of the co-cultures with polySia avDP20 led to the same 
protective effect as seen with Trolox. In total, polySia avDP20 seems to be working 
through reducing the phagocytosis function of iPSdM and macrophages, besides 
inhibiting the release of ROS by phagocytes when they encounter Aβ.  
4.3.4 PolySia avDP20 Effect in LPS Stimulated iPSdM/macrophage-neuron Co-
culture Systems 
LPS is the major immunostimulatory element in cell walls of Gram-negative bacterias, 
which has been studied for a long time to uncover the underlying mechanisms of 
microglia activation. Upon microglial stimulation with LPS, which mainly is recognized 
by Toll-like 4 receptor (TLR-4), these cells become activated and release diverse 
cytotoxic mediators such as NO, IL1-β, TNF-α, various ROS, and other neurotoxic 
factors [40], [135]. Rat neuron treatment with LPS alone was not neurotoxic. However, 
when neurons were cultured under filter inserts containing LPS-activated microglial 
cells, neuronal cell death observed [40]. Further investigation showed that LPS 
increased NO and superoxide secretion from microglial cells, which then reacted, 
formed peroxynitrite and directly damaged neurons. Thus, they concluded that LPS 
neurotoxicity is indirect and via microglial cell activation, but they did not investigate 
phagocytosis function of microglial cells [40]. Afterward, additional studies with 
lipoteichoic acid (LTA) and muramyl dipeptide (MDP), the major immunostimulatory 
elements in cell walls of Gram-positive bacterias, showed that there is a LTA 
concentration dependent reduced neuronal cell number in a rat neuron-microglial cell 
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culture [136]. This reduction was mediated by release of NO by microglial cells and the 
later on production of peroxynitrite, since blocking of either substances significantly 
inhibited neuronal loss [136]. They have not seen an increase in apoptotic cells. They 
concluded that neurons either go through necrotic cell death or that they are rapidly 
removed by activated microglial cells. Later on, it was shown that death of neurons was 
simply prevented by phagocytosis inhibition even without disrupting inflammation [39]. 
The authors of this study declared that in a direct contact neuron-microglia co-culture 
system, LTA and LPS promoted neuronal loss, since microglial separation via transwell 
co-culture was enough to prevent neuronal loss. They assume that LTA or LPS 
microglial cell stimulation leads to more peroxynitrite production and more PS eat me 
signal exposure on neuronal cells, that is recognized by microglial cell receptors and 
leads to phagoptosis of neurites by microglial cells [39]. In this thesis, LPS activated 
iPSdM cells significantly reduced neurite length compare to normal iPSdM cells 
incubation. Furthermore, polySia avDP20 prevented this neurotoxicity. Activated 
macrophages did not show a higher toxicity compared to normal macrophages perhaps 
by non-identical responses of different THP-macrophages batches to LPS. However, 
polySia avDP20 reduced this toxicity. PolySia avDP20 showed this neurotrophic effects 
directly by starting inhibitory signaling, which reduced either neurons phagoptosis or 
prevented ROS production. It is also possible to improve polySia avDP20 effectiveness 
by increasing its concentration, since polySia avDP20 did not change neurons 
metabolic activity till 5 mM concentration.  
Discussions 
 
83 
 
4.4 Summary 
SIGLEC-11 is an inhibitory receptor expressed on microglial cells and macrophages 
and can recognize α 2→8 linked Sias structures. The surface of neuron is decorated by 
different lengths of polySias. PolySia-SIGLEC-11 interaction is important to keep normal 
physiological conditions in neuron-microglia co-culture systems. However, till now it was 
not clear which length of polySia is recognized by SIGLEC-11. 
In this study the low molecular weight polySia with average degree of polymerization 20 
(polySia avDP20), among different polySia lengths, introduced as the best length which 
was recognized by SIGLEC-11. PolySia avDP20 pre-treatment upon Aβ or debris 
stimulation kept superoxide release of microglia/macrophages as low as of untreated 
cells. This effect was not observed when cells were pre-treated with monoSia or 
oligoSias. Furthermore, compared to other polySia lengths (avDP60 and avDP180), 
polySia avDP20 had no effect on the metabolic activity of cells. Knockdown of SIGLEC-
11 was enough to prevent the inhibitory function of polySia avDP20. Additional 
experiments showed that the anti-superoxide effect of polySia avDP20 was as potent as 
Trolox and SOD1. Phagocytosis analysis in iPSdM cells and macrophages revealed 
that polySia avDP20 pre-treatment did reduce uptake of Aβ and debris, which are 
inflammatory phagocytosis stimulants. Neurons were differentiated from pNSCs to 
investigate the consequence of polySia avDP20 addition to co-cultures with 
iPSdM/macrophages. Co-culture of Aβ or LPS stimulated iPSdM/macrophage with 
neurons led to shorter neurite length. This length could stay like untreated neurons if 
polySia avDP20 was present.  
Thus, this study suggests polySia avDP20 as a ligand for SIGLEC-11 receptor to 
reduce the inflammatory response of phagocytes towards provoking stimulants.  
. 
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